A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy
Phase: PHASE2
Conditions: Urinary Bladder Neoplasms
Sponsor: The University of Texas Health Science Center at San Antonio

i 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
Official Study Title: 
 A Phase II Trial of Neoadjuvant AGEN1884 plus AGEN2034 in Combination 
with Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical 
Cystectomy  
(CTMS# 19-0193) 
 
NCT number: NCT04430036 
 
IRB Approval Date: 02.23.2021 
 
 
Unique Protocol ID: CTMS 19-0193 
 
 

ii 
 
 
Protocol: A Phase II Trial of Neoadjuvant AGEN1884 plus AGEN2034 in Combination with 
Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy (CTMS# 
19-0193) 
 
Protocol Version 10 dated 2/23/21  
Summary of Changes 
Cover Page 
Updated cover with current version change 
Reason: Administrative change 
Global 
Minor edits throughout 
Reason: correct spelling, alignment, grammar 
Study Summary 
Added: 
If the total number of pCR is <13, the combination will be deemed as failing to meet the 
primary objective. 
Reason: To clarify, per statistical review. 
Study Sample Size/ 5. STATISTICAL CONSIDERATIONS 
We will submit 17 patients to treatment and fail to reject the null hypothesis and terminate the 
study unless at least 4 5/17 pCRs are observed. If at least 4 5 pCRs are observed, we will 
submit an additional 19 patients to treatment. If at least 13 14/36 pCRs are observed we will 
reject the null hypothesis in favor of the sought improvement in success rate. This modified 
Simon two-stage design yields a type I error rate of 0.044 and power of 0.8 when the true 
response rate is 0.45. 
Reason: Correction, increase by 1 in each section, to align with the original statistical design 
Study Eligibility 
Absolute neutrophil count 
> > 2,000/mcL 
Hemoglobin 
> > 9.0 mg/mL 
Platelets 
> > 100,000/mcL 
Total bilirubin 
within normal limits or known to be elevated 
due to a benign conjugation defect such as 

iii 
 
Gilbert’s syndrome, as evidenced by normal 
conjugated bilirubin level 
AST/ALT 
< 3X institutional normal limits 
Creatinine clearance (CrCl) 
> 50 mL/min/1.73m2, as measured with 24 
hr urine collection or estimated by CKD-EPI, 
whichever is greater 
Reason: Correcting values to be consistent throughout protocol 
4.1.1 
Safety Run-In 
The safety run-in of the study will first enroll three patients at the chosen dose and schedule of 
the combination who will begin treatment with cisplatin and gemcitabine plus AGEN2034 
and AGEN1884 as outlined in the treatment plan. These first 3 patients will be followed to 
completion of day 1 cycle 2 of neoadjuvant therapy in the final patient in this cohort prior to 
enrollment and assessed for DLTs and there will be a pause in enrollment until all three 
complete the DLT period. DLT is defined from events experienced from day 1, cycle 1 
through the day before day 1, cycle 2. If there are no DLTs in the first 3 patients, we will 
proceed to further accrual to stage I of phase II. If there is 1 DLT in the initial 3 patients, we 
will enroll 3 additional patients to the safety run-in. If a second > 2 DLTs is are experienced in 
the initial 3 patients, the study will be terminated. If there is are only 1 2 DLTs in the 6 
patients treated, further accrual can proceed. If there are >2 DLTs in the 6 patients treated, 
the study will be halted. All patients who receive at least two cycles of neoadjuvant therapy 
will be eligible for the primary efficacy endpoint of the study. Those who do not receive 
cystectomy or who receive <2 cycles of neoadjuvant therapy will not be evaluable for the 
primary efficacy endpoint and must be replaced. 
Reason: Provide clarification 
4.1.2 
Phase II, Stage 1 
The study will proceed to the second stage provided the early stopping rules have not been met 
and at least 4 5 adequately treated patients achieve a pCR. Evaluable patients are defined as 
those receiving at least 2 cycles of neoadjuvant immunotherapy plus chemotherapy as 
scheduled. 
Reason: Correction 
5.1 Study Design/Endpoints/ 8. References 
Added: 
The number screened, the number of screen failures by reason, the number enrolled, and 
the number lost to follow-up reason will be tabulated. The Simon two-stage design results 
will be descriptively summarized. Secondary end points will be descriptively summarized. 
Progression free survival will be described with a graphic of the Kaplan-Meier curve, the 
median time to progression, and a 95% confidence interval for the median time to 
progression. Tabular summaries, graphics, and the median time to progression will be 
provided with R [30]. 

iv 
 
30. R Core Team (2013). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R- 
project.org/. 
Reason: Describing statistical calculations. 
4.3 
Treatment Administration 
Added: 
Cisplatin and gemcitabine will be prepared and administered as per standard of care. 
AGEN2034 and AGEN1884 will be prepared and administered as per the Agenus 
pharmacy manual for each agent, respectively. 
Reason: Addition of pharmacy manuals to study. 

Page 1 of 43 
CONFIDENTIAL 
Version 10 dated  
 
 
 
A Phase II Trial of Neoadjuvant AGEN1884 plus AGEN2034 in Combination with Cisplatin-Gemcitabine for 
Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy 
(CTMS# 19-0193) 
Principal Investigator: Chethan Ramamurthy, MD 
Mays Cancer Center 
UT Health San Antonio 
7979 Wurzbach Rd. 
San Antonio, TX 78229 
210-450-1132 
ramamurthyc@uthscsa.edu 
 
 
 
 
 
 
 
 
CTMS# 19-0193 
 
IND# 142737 
 
PROTOCOL V10 
DATE: 2/23/21 

CTMS# 19-0193 
 
INVESTIGATOR’S AGREEMENT 
 
I have read and understand the contents of this clinical protocol for Protocol: A Phase II Trial of Neoadjuvant 
AGEN1884 plus AGEN2034 in Combination with Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer 
Prior to Radical Cystectomy and will adhere to the study requirements as presented, including all statements regarding 
confidentially. In addition, I will conduct the study in accordance with current international conference on harmonization 
(ICH) guidance, Good Clinical Practice (GCP) guidance, the Declaration of Helsinki, US Food and Drug Administration 
(FDA) regulations and local IRB and legal requirements. 
 
 
Name of Investigator: Chethan Ramamurthy, MD 
 
Institution: Mays Cancer Center, UT Health San Antonio 
 
 
 
 
Investigator Signature 
Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 2 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 

Page 3 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
Table of Contents 
Table of Contents .......................................................................................................................3 
1. 
SYNOPSIS ...........................................................................................................................5 
1.1 Muscle Invasive Bladder Cancer (MIBC) ...........................................................................6 
1.2 Neoadjuvant Chemotherapy for MIBC ................................................................................6 
1.3 Checkpoint Inhibition in BC ................................................................................................7 
1.4 Rationale for Combination Checkpoint Inhibition plus Chemotherapy ..............................7 
1.5 Rationale for pT0 as the Clinical Endpoint ..........................................................................8 
Exclusion Criteria ................................................................................................................9 
2. 
OBJECTIVES ....................................................................................................................12 
2.1 Primary Objectives .............................................................................................................12 
2.2 Secondary Objectives .........................................................................................................12 
3. 
BACKGROUND ...............................................................................................................13 
3.1 Muscle Invasive Bladder Cancer (MIBC) .........................................................................13 
3.2 Neoadjuvant Chemotherapy for MIBC ..............................................................................13 
3.3 Checkpoint Inhibition in BC ..............................................................................................13 
3.4 Rationale for Combination Checkpoint Inhibition plus Chemotherapy ............................14 
3.5 Rationale for pT0 as the Clinical Endpoint ........................................................................14 
3.6 Product Description ...........................................................................................................14 
3.6.1 AGEN1884 ............................................................................................................14 
3.6.2 AGEN2034 ............................................................................................................14 
3.7 Dose Rationale ...................................................................................................................15 
4. 
INVESTIGATIONAL PLAN ............................................................................................16 
4.1 Overall Study Design .........................................................................................................16 
4.1.1 
Safety Run-In .........................................................................................................16 
4.1.2 
Phase II, Stage 1 .....................................................................................................16 
4.1.3 
Phase II, Stage 2 .....................................................................................................16 
4.2 Patient Selection .................................................................................................................16 
4.2.1 
Inclusion Criteria ...................................................................................................16 
4.2.3 Inclusion of Women and Minorities ......................................................................18 
4.3 Treatment Administration ..................................................................................................18 
4.4 Dose Modifications and Toxicity Management .................................................................19 
4.5 Study Safety Review ..........................................................................................................28 
4.5.1 
Study Safety Review Committee ...........................................................................28 
4.5.2 
Dose-Limiting Toxicities .......................................................................................28 
4.6 Study Schedule ...................................................................................................................29 
4.7 Demographics and Screening Procedures ..........................................................................30 
4.8 Correlative Biology ............................................................................................................30 
4.9 Disease Assessments ..........................................................................................................30 
4.9.1 
Imaging ..................................................................................................................30 

Page 4 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
4.9.2 
Pathologic Response Criterion ...............................................................................30 
4.10 
Safety Assessments ......................................................................................................32 
5. STATISTICAL CONSIDERATIONS ...............................................................................34 
6. DATA COLLECTION ......................................................................................................35 
7. DATA REPORTING / REGULATORY REQUIREMENTS ..........................................35 
8. References ...........................................................................................................................42 

Page 5 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
1. 
SYNOPSIS 
 
Trial Title 
A Phase II Trial of Neoadjuvant AGEN1884 plus AGEN2034 in Combination with 
Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy 
Trial Number 
CTMS# 19-0193 
Sponsor 
Mays Cancer Center, UT Health San Antonio 
Phase 
Phase II 
Names of 
Investigational 
Products 
AGEN1884 
AGEN2034 
Number of 
Study Sites 
1 (United States) 
Planned 
Number of 
Subjects 
Phase II: 36 subjects 
Study 
Population 
Subjects ≥18 years of age who have muscle invasive urothelial cancer of the bladder eligible for 
neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy 
Study 
Summary 
This is a Phase II trial to establish safe and tolerable AGEN1884 plus AGEN2034 doses in 
combination with neoadjuvant cisplatin and gemcitabine to enable stage 1 of a Simon 2-stage 
trial to evaluate clinical benefits of the addition of neoadjuvant AGEN1884 plus AGEN2034 
concurrent with cisplatin and gemcitabine neoadjuvant chemotherapy in subjects who have 
muscle-invasive, non-metastatic (cT2-4N0-1M0) urothelial bladder cancers and are eligible for 
cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy. 
The study will begin with a 3+3 design safety run-in to establish the safety of this combination, 
with a minimum of 6 and a maximum of 9 patients. The Stage 1 portion of the Simon 2-stage 
design phase II trial will enroll 17 subjects based on assumptions and calculations set forth. The 
Simon 2-stage design halts the trial for futility for < 4 tumor downstage responses in the first 17 
patients. Otherwise, an additional 19 patients will receive AGEN1884 plus AGEN2034 
concurrent with cisplatin and gemcitabine chemotherapy in stage 2. If the total number of pCR 
is <13, the combination will be deemed as failing to meet the primary objective. 
Each experimental treatment cycle is 21 days and matched to the 21-day chemotherapy cycles. 
AGEN2034 is given on day 1 of each cycle, for a total of 4 chemoimmunotherapy cycles, 
whereas AGEN1884 is given on day 1 of cycles 1 and 3 only, for a total of 2 cycles, followed in 
no longer than 10 weeks by radical cystectomy. The primary endpoint is pathologic tumor 
downstaging of >T2 to T0 and is compared to historical controls. Assuming a historical 25% 
rate of downstaging, enrollment of 36 total patients in the full phase II trial has 80% power to 
detect a 45% pathologic complete response rate in the phase II portion of the trial. 

Page 6 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
Trial 
Objectives 
Primary Objectives 
• 
To estimate the pathologic tumor downstaging of >T2 to pT0 rate using neoadjuvant 
AGEN1884 plus AGEN2034 in combination with cisplatin-gemcitabine 
chemotherapy in the treatment of muscle-invasive bladder cancer in patients eligible 
for cisplatin-based chemotherapy. 
Secondary Objectives 
• 
To evaluate the safety and tolerability of using AGEN1884 plus AGEN2034 plus 
cisplatin and gemcitabine chemotherapy in the neoadjuvant treatment of muscle- 
invasive bladder cancer prior to radical cystectomy 
• 
To estimate pathologic downstaging of ≥T2 to <T2 rate 
• 
To investigate biological outcomes that could predict treatment efficacy 
Exploratory Objective 
• 
To correlate clinical outcomes with immune and biologic endpoints and identify patient 
and tumor characteristics that can predict treatment responses 
Background 
1.1 Muscle Invasive Bladder Cancer (MIBC) 
Bladder cancer (BC) is the fourth most common malignancy in US men, with 79,030 new 
annual cases causing an estimated 16,780 deaths in the US in 2017. The majority of cases are 
superficial tumors, managed by local therapies. However, once muscle invasion is identified 
outcomes are much poorer, with approximately one-half of patients dying of their disease.1 For 
patients with MIBC, surgery alone achieves a poor outcome, with a 5-year survival rate of 40- 
50%. Neoadjuvant cisplatin-based chemotherapy regimens have demonstrated a modest but 
absolute benefit in overall survival of 5-8% compared with surgery alone. Thus, while the 
standard of care in the treatment of MIBC is neoadjuvant cisplatin-based chemotherapy 
followed by radical cystectomy, there is a need for improvement. 
1.2 Neoadjuvant Chemotherapy for MIBC 
A pivotal trial randomized patients to three 28-day cycles of neoadjuvant MVAC 
(methotrexate, vinblastine, Adriamycin, cisplatin) plus cystectomy versus cystectomy alone, 
and found a 14% (p=0.06) improvement in overall survival in the combination therapy group, 
establishing neoadjuvant cisplatin-based chemotherapy as the standard of care.2 The pathologic 
complete response (pCR) rate was 38% in the neoadjuvant MVAC arm. However, the classic 
MVAC regimen carried a high rate of grade 3/4 toxicity. Subsequent studies have refined the 
platinum containing regimen. After a study demonstrating improved toxicity with a dose-dense 
schedule of MVAC (ddMVAC) in metastatic urothelial cancer, two single arm phase II studies 
have demonstrated comparable pCR rates with neoadjuvant ddMVAC and classic MVAC. One 
study utilized four cycles of ddMVAC and found a pathologic response rate of 49%, with a 
pCR rate of 26%.3 Another study used three cycles of ddMVAC, which yielded a pathologic 
response rate of 53% and a pCR rate of 38%.4 These studies have led many experts and 
consensus guidelines such as the National Comprehensive Cancer Network (NCCN) to 
recommend a dose dense schedule of MVAC over classic MVAC.5 
However, the multidrug MVAC regimen is not suitable for all patients, particularly the elderly 
bladder cancer patient with potential for cardiovascular comorbidities. Gemcitabine was found 
to be an active agent in advanced or metastatic urothelial cancer,6 and a randomized phase III 
trial in patients with metastatic urothelial cancer comparing gemcitabine-cisplatin (GC) to 
classic MVAC found improved toxicity and similar efficacy with GC.7,8 This use of GC has 
been extrapolated to the neoadjuvant setting, and large population based studies indicate that of 
those receiving neoadjuvant chemotherapy for MIBC, the most commonly used regimen is 

Page 7 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
GC.9 The NCCN also includes GC among the preferred perioperative chemotherapy regimens 
for MIBC.5 
There are two primary dosing schedules for GC, a 21-day schedule and a 28-day schedule. The 
21-day schedule was found to have similar dose intensity and better compliance profile than the 
28-day schedule in a randomized phase II trial, so it is commonly preferred.10 
1.3 Checkpoint Inhibition in BC 
BC tumors typically carry among the highest cancer mutational loads known,11 which correlate 
with the best responses to immunotherapies in other cancers.12 Thus, the rationale for BC 
immunotherapy is strong, further evidenced by recent FDA approvals of two types of BC 
immunotherapies, antibodies blocking PD-L1 (αPD-L1) or PD-1 (αPD-1) immune checkpoint 
molecules. 
PD-L1 is an immune checkpoint molecule that negatively regulates T cell functions through its 
known receptors PD-1 and CD80,13 and is immunopathogenic in many cancers.14 αPD-L1 has 
demonstrated remarkable clinical efficacy against a variety of cancers, including recent FDA- 
approvals of αPD-L1 for BC. PD-1 is also an immune checkpoint molecule and αPD-1 is also 
FDA-approved to treat BC. Despite major efficacy in a selected few patients, these immune 
checkpoint inhibitor antibodies are not typically curative or universally effective, with an average 
~30% response rate. CTLA-4 is the third immune checkpoint molecule for which an immune 
checkpoint inhibitor antibody is FDA-approved (melanoma, renal cell carcinoma). While αPD-1 
has significant activity as monotherapy in metastatic BC, the combination of αPD-1 and αCTLA- 
4 at selected doses led to even higher response rates and improvements in survival for patients 
with pretreated metastatic urothelial carcinoma.15 
Combinations of two immune checkpoint inhibitors have demonstrated superior response rates 
to either single agent. For example, the combination of αPD-1 plus αCTLA-4 is FDA-approved 
for selected melanomas, as the combination provides superior response rates to either single 
agent.12 The combination is also approved for the treatment of renal cell carcinoma.16 Likewise, 
αPD-1 plus αCTLA-4 provides superior response rates to either single agent to treat certain non- 
small cell and small cell lung cancers.17,18 
1.4 Rationale for Combination Checkpoint Inhibition plus Chemotherapy 
The most successful combination of chemotherapy with checkpoint inhibitors thus far has been 
in lung cancer. The KEYNOTE-021 study was a randomized phase II trial of chemotherapy- 
naïve advanced non-squamous, non-small cell lung cancer patients.19 Based on phase I data 
showing the highest ORR with the combination of carboplatin and pemetrexed with 
pembrolizumab, this trial randomized patients to receive either 4 cycles of carboplatin- 
pemetrexed with continued pemetrexed maintenance alone or the same regimen combined with 
pembrolizumab 200 mg every 3 weeks for 24 months. The pembrolizumab plus chemotherapy 
group (n = 60) had an improved ORR of 55% (95% CI, 42-68%) compared with the 
chemotherapy alone group (n = 63), which had an ORR of 29% (95% CI, 18-41%). Median 
PFS in the combination group was 13.0 months (95% CI, 8.3-not reached) compared with 8.9 
months (95% CI, 4.4-10.3) in the chemotherapy alone group. The rate of grade 3 or higher AEs 
was slightly higher with the combination (39%) than with chemotherapy alone (26%) but did 
not lead to an increased discontinuation rate (10% versus 13%, respectively). Interestingly, 
responses were seen regardless of tumor PD-L1 expression, with 57% ORR (95% CI, 34-79) in 
the PD-L1 <1% group and 54% (95% CI, 37-70) in the PD-L1 >1% group. 
GC chemotherapy is an established standard of care in the treatment of MIBC, as detailed 
above. Furthermore, both agents have been shown to enhance antitumoral immune activity. 
Cisplatin can upregulate MHC class I expression, promote recruitment and proliferation of 
effector T cells, downregulate immunosuppressive elements of the tumor microenvironment, 
and upregulate activity of cytotoxic effectors.20 Similarly, gemcitabine too has been shown to 

Page 8 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
increase antigen presentation and MHC class I expression as well as reduce population of 
myeloid-derived suppressor cells in vitro.21 The regimen is also most effectively administered 
on a 21-day schedule, similar to the investigational agents. Thus, this is an ideal chemotherapy 
backbone for this study of combination chemoimmunotherapy. 
1.5 Rationale for pT0 as the Clinical Endpoint 
Pathologic downstaging to pT0 in BC at cystectomy is strongly associated with long-term 
disease-free survival. For patients with pT0 at time of cystectomy (pathologic complete response 
or pCR), 5-year overall survival was 85%, compared to only 45% for patients with residual 
disease at time of cystectomy.22 This endpoint has been used to justify dose-dense MVAC as a 
standard of care based on results of a phase II clinical trial, and is currently used as the primary 
endpoint of several ongoing neoadjuvant cystectomy trials.4 
The reported pCR rates to cisplatin-based neoadjuvant chemotherapy vary widely, ranging from 
15-41%.4,23-26 A large, recent cross-sectional analysis of 332 patients treated at an academic 
institution who received neoadjuvant chemotherapy prior to cystectomy reported a pCR rate of 
24.5% in the 204 patients receiving neoadjuvant GC.26 
Study Sample 
Size 
The study will begin with a safety run-in. Three patients will be treated with the combination 
and observed for a DLT during the first cycle of treatment. After no DLT is observed in the first 
3 patients, an additional 3 patients will be treated and observed for DLTs. If the specified safety 
criteria are met, the study will proceed to the full Simon two-stage design. 
The overall study employs a modified Simon two-stage design with a minmax design, enrolling 
17 patients in stage I and subsequently 19 more patients in stage II if early termination criteria 
are not met. There are early termination criteria for futility. To be evaluable for the primary 
endpoint in phase II, patients must have received at least two cycles of neoadjuvant therapy, 
otherwise they must be replaced. Using a historical pCR rate of 0.25 as the null hypothesis, we 
will seek to demonstrate a rate of 0.45. The reported pCR rates to cisplatin-based neoadjuvant 
chemotherapy vary widely, ranging from 15-41%4,23-26. We have chosen a rate of 25% based on 
the pCR rate for GC from a large, recent cross-sectional analysis of 332 patients who received 
neoadjuvant chemotherapy prior to cystectomy.26 We will submit 17 patients to treatment and 
fail to reject the null hypothesis and terminate the study unless at least 5/17 pCRs are observed. 
If at least 5 pCRs are observed, we will submit an additional 19 patients to treatment. If at least 
14/36 pCRs are observed we will reject the null hypothesis in favor of the sought improvement 
in success rate. This modified Simon two-stage design yields a type I error rate of 0.044 and 
power of 0.8 when the true response rate is 0.45. 
Study 
Eligibility 
Inclusion Criteria 
1. Diagnosis of muscle-invasive, non-metastatic urothelial carcinoma of the bladder, 
cT2-4, N0-1, M0 
2. Eligible to receive cisplatin-based chemotherapy, with eligibility defined as 
meeting all of the following criteria: 
a) Eastern Cooperative Oncology Group performance status of 0-1 
b) Creatinine clearance (CrCl) of ≥50 mL/min, as measured by 24-hour urine 
collection or estimated by the CKD-EPI equation. Patients with CrCl 
between 50 – 60 mL/min are eligible for the study but will receive split 
dose cisplatin 
c) Grade ≤2 hearing loss 
d) Grade ≤2 peripheral neuropathy 
e) New York Heart Association Class < III congestive heart failure 

Page 9 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
3. Eligible to receive gemcitabine as dosed here 
4. Patients must have organ and marrow function meeting the criteria below: 
Absolute neutrophil count 
> 2,000/mcL 
Hemoglobin 
> 9.0 mg/mL 
Platelets 
> 100,000/mcL 
Total bilirubin 
within normal limits or known to be elevated 
due to a benign conjugation defect such as 
Gilbert’s syndrome, as evidenced by normal 
conjugated bilirubin level 
AST/ALT 
< 3X institutional normal limits 
Creatinine clearance (CrCl) 
> 50 mL/min/1.73m2, as measured with 24 
hr urine collection or estimated by CKD-EPI, 
whichever is greater 
5. Signed, written informed consents to allow transfer of tumor tissue and production 
of peptides and to receive experimental treatment and monitoring if agreeable, or 
monitoring without experimental treatment otherwise 
6. Age ≥18 years 
7. Available fresh tissue from surgical excision. If fresh tissue is not available, 
archival tissue may be used. 
8. Female subjects of childbearing potential must have a negative serum pregnancy 
test at screening (within 72 hours of first dose of study medication). Non- 
childbearing potential (other than by medical reasons) is defined as 1 of the 
following: 
a) 
≥45 years of age and amenorrheic for >1 year by self-report. 
b) Amenorrheic for >2 years without a hysterectomy and oophorectomy, and 
follicle-stimulating hormone value in the postmenopausal range upon pretrial 
(screening) evaluation. 
c) Status post-hysterectomy, -oophorectomy, or –tubal ligation. 
9. If of childbearing potential, female subjects must be willing to use adequate birth 
control during the study, starting with the screening visit through 120 days after the 
last dose of study therapy. 
10. Male subjects with a female partner(s) of childbearing potential must agree to use a 
condom throughout the trial, starting with the screening visit through 120 days after 
the last dose of study therapy. Males with pregnant partners must agree to use a 
condom; no additional method of contraception is required for the pregnant partner. 
Note: Abstinence is acceptable for both female and male subjects if this is the subject’s 
established and preferred contraception method. 
Exclusion Criteria 
1. Subjects must not have previously received a checkpoint inhibitor ie, anti-PD-1, 
anti-PD L1, or anti CTLA-4 antibody. 
2. Subjects must not have previously received anticancer medications or 
investigational drugs for the disease under study within the following windows: 

Page 10 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
a. ≤ 28 days for prior monoclonal antibody used for anticancer therapy, with 
the exception of denosumab 
b. ≤ 7 days for immunosuppressive treatment for any reason, with the 
following exceptions: 
i. Physiologic steroid replacement for adrenal insufficiency (e.g., <10 mg 
prednisone per day) is permitted. 
ii. Use of inhaled or topical corticosteroid for radiographic procedures is 
permitted. 
c. Systemic corticosteroids < 7 days are not allowed except as defined above. 
d. ≤ 28 days before first dose of study drug for all other investigational study 
drugs or devices 
3. Has persisting toxicity related to prior therapy of National Cancer Institute 
Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE) 
Grade >1 severity. 
Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable. 
4. Has known severe hypersensitivity reactions to fully human monoclonal antibodies 
(NCI-CTCAE Version 5.0 Grade ≥3), any history of anaphylaxis, or uncontrolled 
asthma. 
5. Active or history of any autoimmune disease (subjects with diabetes type 1, vitiligo, 
psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive  
treatment are eligible). Patients with a history of inflammatory bowel disease 
(including Crohn's disease and ulcerative colitis) and autoimmune disorders such as 
rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus 
Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are 
excluded from this study. 
6. Any condition requiring systemic treatment with corticosteroids (>10mg daily 
prednisone equivalents) or other immunosuppressive medications within 14 days 
prior to first dose of study drug. Inhaled steroids and adrenal replacement steroids 
doses >10mg daily prednisone equivalents are permitted in the absence of active 
autoimmune disease. 
7. Uncontrolled intercurrent illness, including but not limited to uncontrolled 
infection, interstitial lung disease or active, non-infectious pneumonitis, 
symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac 
arrhythmia, or social situations that would limit compliance with study 
requirements in the opinion of the treating investigator or medical monitor. 
8. History of intolerance or allergic reactions attributed to compounds of similar 
chemical or biologic composition to AGEN1884 or AGEN2034. 
9. Women who are pregnant or breastfeeding. 
10. Receipt of a live vaccine within 30 days prior to the first dose of study drug. 
11. Inability to adhere to the protocol. 
Dosage and 
Administration 
AGEN1884 1mg/kg q6 weeks plus AGEN2034 300mg q3 weeks with cisplatin 70 mg/m2 day 1 
and gemcitabine 1000 mg/m2 days 1 and 8 of a 21 day cycle to a maximum of 4 cycles. 
AGEN1884 plus AGEN2034 are given on day 1 of 21-day cycles 1 and 3 and AGEN2034 is 
given on day 1 of cycle 2, after cisplatin and gemcitabine. AGEN1884 is given before 
AGEN2034 when both are given on the same day. 
Planned Trial 
Duration 
Subject accrual: Estimated 2 years 
Study duration: >60-64 weeks/subject 
• 
Screening: 2-4 weeks 

Page 11 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
• 
Experimental treatment period: 12 weeks 
• 
Follow-up period:2 years 
Schedule of 
Visits and 
Assessments 
Screening 
This phase will take approximately 2 weeks/patient 
Treatment and Evaluation Phase 
The treatment and evaluation phase for patients undergoing experimental treatments consists of 
cycles with cisplatin and gemcitabine chemotherapy plus concurrent AGEN1884 and/or 
AGEN2034, plus additional periodic immune, biologic and clinical monitoring. 
Safety: Safety will be assessed at every visit by frequency, severity, and duration of treatment- 
emergent adverse events per National Cancer Institute Common Terminology Criteria for 
Adverse Events version 5.0, physical examinations, vital signs, weight, clinical laboratory tests, 
and ECOG performance status. Collection of adverse events will begin at time of first study 
treatment. 
Clinical: Disease evaluations will be conducted prior to the initial dose of study treatment, and 
every 3 weeks during experimental treatments. Prior to Cycle 3 Day 1, restaging imaging 
evaluation will be performed. At the end of experimental treatment, patients will proceed to 
radical cystectomy and be evaluable for the primary endpoint of pathologic complete response 
(pT0). 
Immunogenicity: To determine induction of subject’s immunoreactivity against bladder cancer 
Follow-up Phase 
End-of-Treatment (or Discontinuation) Visit (14 days ± 5 days after last treatment) 
Subjects who discontinue experimental treatment prematurely for an adverse event will undergo 
a full safety evaluation at the time of discontinuation and will be followed for survival for 1 
year from first study treatment. 
Final Safety Visit 
A final safety visit may be performed 30 (± 7) days after the last experimental treatment 
administration at the discretion of the investigator. Subjects with an ongoing adverse drug 
reaction at this visit must be followed until the event resolves, becomes stable, or is 
considered not to be clinically significant by the investigator. 
Survival Follow-up 
Subjects will be followed (by phone or office visit) every 12 weeks from their cystectomy for 2 
years to assess survival. 
Endpoints 
Primary Endpoints 
• 
Pathologic tumor downstaging of >T2 to pT0 
Secondary Endpoints 
• 
CTCAE v. 5.0 
• 
Pathologic downstaging to <T2 
• 
Completion of surgery 
• 
Progression-free survival at 1 year 
Exploratory Endpoints 
• 
Correlative immune outcomes 

Page 12 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
2. 
OBJECTIVES 
2.1 
Primary Objectives 
• 
To estimate the pathologic tumor downstaging of >T2 to pT0 rate using neoadjuvant AGEN1884 
plus AGEN2034 in combination with cisplatin-gemcitabine chemotherapy in the treatment of 
muscle-invasive bladder cancer in patients eligible for cisplatin-based chemotherapy 
2.2 
Secondary Objectives 
• 
To evaluate the safety and tolerability of using AGEN1884 plus AGEN2034 plus cisplatin and 
gemcitabine chemotherapy in the neoadjuvant treatment of muscle-invasive bladder cancer prior to 
radical cystectomy, 
• 
To estimate pathologic downstaging of ≥T2 to <T2 rate 
• 
To investigate biological outcomes that could predict treatment efficacy 
2.3 
Exploratory Objectives 
• 
To correlate clinical outcomes with immune and biologic endpoints and identify patient and 
tumor characteristics that can predict treatment responses 

Page 13 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
3. 
BACKGROUND 
3.1 Muscle Invasive Bladder Cancer (MIBC) 
Bladder cancer (BC) is the fourth most common malignancy in US men, with 79,030 new annual cases causing an 
estimated 16,780 deaths in the US in 2017. The majority of cases are superficial tumors, managed by local therapies. 
However, once muscle invasion is identified outcomes are much poorer, with approximately one-half of patients dying of 
their disease.1 For patients with MIBC, surgery alone achieves a poor outcome, with a 5-year survival rate of 40-50%. 
Neoadjuvant cisplatin-based chemotherapy regimens have demonstrated a modest but absolute benefit in overall survival 
of 5-8% compared with surgery alone. Thus, while the standard of care in the treatment of MIBC is neoadjuvant 
cisplatin-based chemotherapy followed by radical cystectomy, there is a need for improvement. 
3.2 Neoadjuvant Chemotherapy for MIBC 
A pivotal trial randomized patients to three 28-day cycles of neoadjuvant MVAC (methotrexate, vinblastine, Adriamycin, 
cisplatin) plus cystectomy versus cystectomy alone, and found a 14% (p=0.06) improvement in overall survival in the 
combination therapy group, establishing neoadjuvant cisplatin-based chemotherapy as the standard of care.2 The 
pathologic complete response (pCR) rate was 38% in the neoadjuvant MVAC arm. However, the classic MVAC regimen 
carried a high rate of grade 3/4 toxicity. Subsequent studies have refined the platinum containing regimen. After a study 
demonstrating improved toxicity with a dose-dense schedule of MVAC (ddMVAC) in metastatic urothelial cancer, two 
single arm phase II studies have demonstrated comparable pCR rates with neoadjuvant ddMVAC and classic MVAC. One 
study utilized four cycles of ddMVAC and found a pathologic response rate of 49%, with a pCR rate of 26%.3 Another 
study used three cycles of ddMVAC, which yielded a pathologic response rate of 53% and a pCR rate of 38%.4 These 
studies have led many experts and consensus guidelines such as the National Comprehensive Cancer Network (NCCN) to 
recommend a dose dense schedule of MVAC over classic MVAC.5 
However, the multidrug MVAC regimen is not suitable for all patients, particularly the elderly bladder cancer patient with 
potential for cardiovascular comorbidities. Gemcitabine was found to be an active agent in advanced or metastatic 
urothelial cancer,6 and a randomized phase III trial in patients with metastatic urothelial cancer comparing gemcitabine- 
cisplatin (GC) to classic MVAC found improved toxicity and similar efficacy with GC.7,8 This use of GC has been 
extrapolated to the neoadjuvant setting, and large population based studies indicate that of those receiving neoadjuvant 
chemotherapy for MIBC, the most commonly used regimen is GC.9 The NCCN also includes GC among the preferred 
perioperative chemotherapy regimens for MIBC.5 
There are two primary dosing schedules for GC, a 21-day schedule and a 28-day schedule. The 21-day schedule was 
found to have similar dose intensity and better compliance profile than the 28-day schedule in a randomized phase II trial, 
so it is commonly preferred.10 
3.3 Checkpoint Inhibition in BC 
BC tumors typically carry among the highest cancer mutational loads known,11 which correlate with the best responses to 
immunotherapies in other cancers.12 Thus, the rationale for BC immunotherapy is strong, further evidenced by recent FDA 
approvals of two types of BC immunotherapies, antibodies blocking PD-L1 (αPD-L1) or PD-1 (αPD-1) immune checkpoint 
molecules. 
 
PD-L1 is an immune checkpoint molecule that negatively regulates T cell functions through its known receptors PD-1 and 
CD80,13 and is immunopathogenic in many cancers.14 αPD-L1 has demonstrated remarkable clinical efficacy against a 
variety of cancers, including recent FDA-approvals of αPD-L1 for BC. PD-1 is also an immune checkpoint molecule and 
αPD-1 is also FDA-approved to treat BC. Despite major efficacy in a selected few patients, these immune checkpoint 
inhibitor antibodies are not typically curative or universally effective, with an average ~30% response rate. CTLA-4 is the 
third immune checkpoint molecule for which an immune checkpoint inhibitor antibody is FDA-approved (melanoma, renal 
cell carcinoma). While αPD-1 has significant activity as monotherapy in metastatic BC, the combination of αPD-1 and 
αCTLA-4 at selected doses led to even higher response rates and improvements in survival for patients with pretreated 
metastatic urothelial carcinoma.15 
 
Combinations of two immune checkpoint inhibitors have demonstrated superior response rates to either single agent. For 
example, the combination of αPD-1 plus αCTLA-4 is FDA-approved for selected melanomas, as the combination provides 
superior response rates to either single agent.12 The combination is also approved for the treatment of renal cell carcinoma.16 

Page 14 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
Likewise, αPD-1 plus αCTLA-4 provides superior response rates to either single agent to treat certain non-small cell and 
small cell lung cancers.17,18 
3.4 Rationale for Combination Checkpoint Inhibition plus Chemotherapy 
The most successful combination of chemotherapy with checkpoint inhibitors thus far has been in lung cancer. The 
KEYNOTE-021 study was a randomized phase II trial of chemotherapy-naïve advanced non-squamous, non-small cell 
lung cancer patients.19 Based on phase I data showing the highest ORR with the combination of carboplatin and 
pemetrexed with pembrolizumab, this trial randomized patients to receive either 4 cycles of carboplatin-pemetrexed with 
continued pemetrexed maintenance alone or the same regimen combined with pembrolizumab 200 mg every 3 weeks for 
24 months. The pembrolizumab plus chemotherapy group (n = 60) had an improved ORR of 55% (95% CI, 42-68%) 
compared with the chemotherapy alone group (n = 63), which had an ORR of 29% (95% CI, 18-41%). Median PFS in the 
combination group was 13.0 months (95% CI, 8.3-not reached) compared with 8.9 months (95% CI, 4.4-10.3) in the 
chemotherapy alone group. The rate of grade 3 or higher AEs was slightly higher with the combination (39%) than with 
chemotherapy alone (26%) but did not lead to an increased discontinuation rate (10% versus 13%, respectively). 
Interestingly, responses were seen regardless of tumor PD-L1 expression, with 57% ORR (95% CI, 34-79) in the PD-L1 
<1% group and 54% (95% CI, 37-70) in the PD-L1 >1% group. 
 
GC chemotherapy is an established standard of care in the treatment of MIBC, as detailed above. Furthermore, both 
agents have been shown to enhance antitumoral immune activity. Cisplatin can upregulate MHC class I expression, 
promote recruitment and proliferation of effector T cells, downregulate immunosuppressive elements of the tumor 
microenvironment, and upregulate activity of cytotoxic effectors.20 Similarly, gemcitabine too has been shown to increase 
antigen presentation and MHC class I expression as well as reduce population of myeloid-derived suppressor cells in 
vitro.21 The regimen is also most effectively administered on a 21-day schedule, similar to the investigational agents. 
Thus, this is an ideal chemotherapy backbone for this study of combination chemoimmunotherapy. 
 
3.5 Rationale for pT0 as the Clinical Endpoint 
Pathologic downstaging to pT0 in BC at cystectomy is strongly associated with long-term disease-free survival. For patients 
with pT0 at time of cystectomy (pathologic complete response or pCR), 5-year overall survival was 85%, compared to only 
45% for patients with residual disease at time of cystectomy.22 This endpoint has been used to justify dose-dense MVAC as 
a standard of care based on results of a phase II clinical trial, and is currently used as the primary endpoint of several ongoing 
neoadjuvant cystectomy trials.4 
 
The reported pCR rates to cisplatin-based neoadjuvant chemotherapy vary widely, ranging from 15-41%.4,23-26 A large, 
recent cross-sectional analysis of 332 patients treated at an academic institution who received neoadjuvant chemotherapy 
prior to cystectomy reported a pCR rate of 24.5% in the 204 patients receiving neoadjuvant GC.26 
3.6 Product Description 
3.6.1 
AGEN1884 
AGEN1884 is a fully human IgG1 antibody. There was no apparent pattern seen for SAEs or AEs ≥ grade 3 related to 
AGEN1884 or AGEN1884 dose. Most AEs were of mild-moderate severity and manageable by standard care. In Phase I 
trials, AGEN1884 was well tolerated in combination with the FDA-approved αPD-1 agent pembrolizumab. AGEN1884 
was also well-tolerated when combined with the αPD-1 antibody AGEN2034. Its mechanisms of action, pharmacokinetic 
properties, AE profile and single agent efficacy are similar to FDA-approved ipilimumab (Agenus Investigator Brochure). 
As of ASCO 2018, AGEN1884 delivered clinical benefit in 31% of patients. A complete and durable response was 
observed in a patient with angiosarcoma. 
3.6.2 
AGEN2034 
AGEN2034 is a human IgG4 antibody. In 24 evaluable subjects, up to 10 mg/kg every 2 weeks was safe and tolerable. Its 
safe combination with AGEN1884 is shown above. Its mechanisms of action, pharmacokinetic properties, AE profile and 
clinical efficacy are similar to FDA-approved anti-PD-1 agents nivolumab or pembrolizumab (Agenus Investigator 
Brochure). As of ASCO 2018, AGEN2034 delivered clinical benefit in 42% of patients. 

Page 15 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
3.7 Dose Rationale 
Doses and schedule for AGEN1884 and AGEN2034 were based on Agenus phase I experience with these agents, with 
initial dosing based on FDA approval of similar anti-CTLA-4 and anti-PD-1 antibodies, respectively in melanoma. In data 
presented from the Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With 
Advanced/Refractory Solid Tumors at the European Society of Medical Oncology Annual Meeting 2018 (Abstract 
1168P), 10 patients had been treated with AGEN2034 1 mg/kg q2 weeks + AGEN1884 1mg/kg q6 weeks and another 10 
patients with AGEN2034 3 mg/kg q2 weeks + AGEN 1884 1 mg/kg q6 weeks. As of July 2018, no DLTs had been 
observed and no treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. One patient in the 
AGEN2034 1 mg/kg cohort had a serious TEAE considered related to treatment (diarrhea), and two patients in the 
AGEN2034 3 mg/kg cohort had a serious TEAE considered related to treatment (lower respiratory tract infection, 
pulmonary embolism). Based on these results, the phase 2 recommended dosing was determined as AGEN2034 3 mg/kg 
q2w + AGEN1884 1 mg/kg q6w. Preliminary clinical safety and response data are available from investigations of 
AGEN1884 as monotherapy [Study C-500-01], AGEN2034 as monotherapy [Study C-700-01], and 
AGEN1884+AGEN2034 as combination therapy [Study C-550-01]. Based on prior experience with combining 
chemotherapy with checkpoint inhibitors, such as from the KEYNOTE-021 study, there are not expected to be 
overlapping toxicities given distinct mechanisms of action.27 
 
At the 01 November 2018 FDA End-of-Phase-1 (EOP1) meeting, FDA agreed to a fixed (flat) dose for AGEN2034 for 
Study C-750-01/Study GOG-3028. For a patient of average body weight, AGEN2034 delivered as 3 mg/kg q2w (body 
weight adjusted dose) or 300 mg q3w (flat dose) is expected to deliver similar AGEN2034 dose and systemic exposure 
over a 6-week treatment cycle. To allow for coordination with the 21-day chemotherapy backbone schedule, we have 
chosen the dose of AGEN2034 300 mg q3w and AGEN1884 1 mg/kg q6w. Moreover, the choice of a flat dose for 
AGEN2034 is expected to reduce dosing errors and reduce drug wastage. 

Page 16 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
4. 
INVESTIGATIONAL PLAN 
4.1 
Overall Study Design 
This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 
concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder cancer 
prior to radical cystectomy. We will begin with an initial safety run-in to establish the safety of the combination prior to 
expansion to the full planned phase II. The overall phase II will be an open-label, single arm study in two stages to 
evaluate the efficacy of the combination in pathologic downstaging of MIBC. Patients will receive four 21-day cycles of 
neoadjuvant therapy consisting of cisplatin and gemcitabine plus AGEN2034 in all 4 cycles and AGEN1884 in cycles 1 
and 3. Patients will proceed to radical cystectomy within 10 weeks after the final dose of this therapy. The primary 
endpoint of pathologic tumor downstaging will be assessed at the time of cystectomy. 
4.1.1 
Safety Run-In 
The safety run-in of the study will first enroll three patients who will begin treatment with cisplatin and gemcitabine plus 
AGEN2034 and AGEN1884 as outlined in the treatment plan. These first 3 patients will be assessed for DLTs and there 
will be a pause in enrollment until all three complete the DLT period. DLT is defined from events experienced from day 
1, cycle 1 through the day 1, cycle 2. If there are no DLTs in the first 3 patients, we will proceed to further accrual to stage 
I of phase II.  If there is 1 DLT in the initial 3 patients, we will enroll 3 additional patients to the safety run-in. If > 2  
DLTs are experienced in the initial 3 patients, the study will be terminated. If there are only 2 DLTs in the 6 patients 
treated, further accrual can proceed. If there are >2 DLTs in the 6 patients treated, the study will be halted. All patients 
who receive at least two cycles of neoadjuvant therapy will be eligible for the primary efficacy endpoint of the study. 
Those who do not receive cystectomy or who receive <2 cycles of neoadjuvant therapy will not be evaluable for the 
primary efficacy endpoint and must be replaced. 
4.1.2 
Phase II, Stage 1 
In the first stage of phase II of this study, 17 patients will be enrolled. Patients will begin treatment with cisplatin and 
gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. They will be evaluated with each cycle of 
therapy, with radiographic restaging assessment after 2 cycles of therapy and prior to the third cycle of treatment. If no 
disease progression is identified, patients will receive a third and fourth cycle of therapy. Following this neoadjuvant 
regimen, they will proceed to planned surgery following preoperative clearance within 10 weeks of the last dose of 
neoadjuvant therapy. Surgical specimens will be used to assess the primary endpoint of pathologic tumor downstaging to 
pT0. Correlative endpoints will also be measured throughout the study period as specified. The study will proceed to the 
second stage provided the early stopping rules have not been met and at least 5 adequately treated patients achieve a pCR. 
Evaluable patients are defined as those receiving at least 2 cycles of neoadjuvant immunotherapy plus chemotherapy as 
scheduled. Otherwise, that patient must be replaced. 
4.1.3 
Phase II, Stage 2 
If criteria are met to continue to the second stage of the Phase II portion of the study, 19 more patients will be enrolled for 
a total of 36 evaluable patients. Patients will be treated and endpoints evaluated as above. 
4.2 
Patient Selection 
4.2.1 
Inclusion Criteria 
 
1. Diagnosis of muscle-invasive, non-metastatic urothelial carcinoma of the bladder, cT2-4, N0-1, M0 
2. Eligible to receive cisplatin-based chemotherapy, with eligibility defined as meeting all of the 
following criteria: 
a. Eastern Cooperative Oncology Group performance status of 0-1 
b. Creatinine clearance (CrCl) of >50 mL/min, as measured by 24-hour urine collection or 
estimated by the CKD-EPI equation. Patients with CrCl between 50 – 60 mL/min are eligible 
for the study but will receive split dose cisplatin 
c. Grade < 2 hearing loss 
d. Grade < 2 peripheral neuropathy 

Page 17 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
e. New York Heart Association Class < III heart failure 
3. Eligible to receive gemcitabine as dosed here 
4. Patients must have organ and marrow function meeting the criteria below: 
 
Absolute neutrophil count 
> 2,000/mcL 
Hemoglobin 
> 9.0 mg/mL 
Platelets 
> 100,000/mcL 
Total bilirubin 
within normal limits or known to be elevated due to a 
benign conjugation defect such as Gilbert’s syndrome, 
as evidenced by normal conjugated bilirubin level 
AST/ALT 
< 3X institutional normal limits 
Creatinine clearance (CrCl) 
> 50 mL/min/1.73m2, as measured with 24 hr urine 
collection or estimated by CKD-EPI, whichever is 
greater 
5. Signed, written informed consents to allow transfer of tumor tissue and production of peptides and to 
receive experimental treatment and monitoring if agreeable, or monitoring without experimental 
treatment otherwise 
6. Age ≥18 years 
7. Available fresh tissue from surgical excision. If fresh tissue is not available, archival tissue may be 
used. 
8. Female subjects of childbearing potential must have a negative serum pregnancy test at screening 
(within 72 hours of first dose of study medication). Non-childbearing potential (other than by medical 
reasons) is defined as 1 of the following: 
a. ≥ 45 years of age and amenorrheic for >1 year by self-report. 
b. Amenorrheic for >2 years without a hysterectomy and oophorectomy, and follicle- 
stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation. 
c. Status post-hysterectomy, -oophorectomy, or –tubal ligation. 
If of childbearing potential, female subjects must be willing to use adequate birth control during the study, 
starting with the screening visit through 120 days after the last dose of study therapy. 
Male subjects with a female partner(s) of childbearing potential must agree to use a condom throughout 
the trial, starting with the screening visit through 120 days after the last dose of study therapy. Males with 
pregnant partners must agree to use a condom; no additional method of contraception is required for the 
pregnant partner. 
Note: Abstinence is acceptable for both female and male subjects if this is the subject’s established and 
preferred contraception method. 
 
 
4.2.2. 
Exclusion Criteria 
1. Subjects must not have previously received a checkpoint inhibitor ie, anti-PD-1, anti-PD L1, or anti 
CTLA-4 antibody. 
2. Subjects must not have previously received anticancer medications or investigational drugs for the 
disease under study within the following windows: 

Page 18 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
a. ≤ 28 days for prior monoclonal antibody used for anticancer therapy, with the exception of 
denosumab 
b. ≤ 7 days for immunosuppressive treatment for any reason, with the following exceptions: 
i. Physiologic steroid replacement for adrenal insufficiency (e.g., <10 mg prednisone per day) 
is permitted. 
ii. Use of inhaled or topical corticosteroid for radiographic procedures is permitted. 
c. Systemic corticosteroids < 7 days are not allowed except as defined above. 
d. ≤ 28 days before first dose of study drug for all other investigational study drugs or devices 
3. Has persisting toxicity related to prior therapy of National Cancer Institute Common Terminology 
Criteria for Adverse Events version 5.0 (NCI-CTCAE) Grade >1 severity. 
Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable. 
4. Has known severe hypersensitivity reactions to fully human monoclonal antibodies (NCI-CTCAE 
Version 5.0 Grade ≥3), any history of anaphylaxis, or uncontrolled asthma. 
5. Active or history of any autoimmune disease (subjects with diabetes type 1, vitiligo, psoriasis, hypo- 
or hyperthyroid disease not requiring immunosuppressive treatment are eligible). Patients with a 
history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and 
autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], 
Systemic Lupus Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are 
excluded from this study. 
6. Any condition requiring systemic treatment with corticosteroids (>10mg daily prednisone 
equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. 
Inhaled steroids and adrenal replacement steroids doses >10mg daily prednisone equivalents are 
permitted in the absence of active autoimmune disease. 
7. Uncontrolled intercurrent illness, including but not limited to uncontrolled infection, interstitial lung 
disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina 
pectoris, uncontrolled cardiac arrhythmia, or social situations that would limit compliance with study 
requirements in the opinion of the treating investigator or medical monitor. 
8. History of intolerance or allergic reactions attributed to compounds of similar chemical or biologic 
composition to AGEN1884 or AGEN2034. 
9. Women who are pregnant or breastfeeding. 
10. Receipt of a live vaccine within 30 days prior to the first dose of study drug. 
11. Inability to adhere to the protocol 
4.2.3 
Inclusion of Women and Minorities 
Both men and women and members of all races and ethnic groups are eligible for this trial and none will be excluded 
based on gender or ethnicity. 
4.3 
Treatment Administration 
AGEN2034 with chemotherapy is always given on day 1 of eligible chemotherapy cycles and AGEN1884 is always given 
on day 1 of cycles 1 and 3. If chemotherapy is held for any reason, AGEN2034 and AGEN1884 are also held, to resume 
concurrent with chemotherapy when chemotherapy resumes. There is no specified time that chemotherapy is withheld that 
will exclude a patient from study, except as noted in the DLT assessment section for the safety run-in. Toxicities 
occurring in any of the 4 neoadjuvant cycles and 7 days thereafter with AGEN1884, AGEN2034 or cisplatin and 
gemcitabine are used to make toxicity assessments of these agents but not necessarily DLTs. 
 
The order of administration will be as follows: 
Premedications 
Tylenol 650 mg oral, antiemetics (including 
dexamethasone, 5HT3 antagonist, NK1 
antagonist, and olanzapine, as per investigator 
discretion). 

Page 19 of 43 
CONFIDENTIAL 
Version 10 dated  2/2/23/21 
 
AGEN2034 
IV infusion (final concentration 1-2 mg/mL), over 
30 minutes, after dilution in sterile, normal saline 
AGEN1884 
IV infusion (final concentration 1-2 mg/mL), over 
30 minutes, after dilution in sterile, normal saline 
Gemcitabine 
IV infusion over 30 minutes 
Cisplatin 
IV infusion over 2 hours 
 
Pre- and post-hydration as well as mannitol administration for cisplatin will be at investigators’ discretion, but at least 2L 
of IV fluids must be given. 
 
Cisplatin and gemcitabine will be prepared and administered as per standard of care. AGEN2034 and AGEN1884 will be 
prepared and administered as per the Agenus pharmacy manual for each agent, respectively. 
4.4 
Dose Modifications and Toxicity Management 
Dose modifications for AGEN1884 and AGEN2034 are not permitted. Treatment may be held for toxicity as per accepted 
guidelines. Toxicities related to AGEN1884 and AGEN2034 are graded and managed per the SOC for toxicities related to 
the similar agents ipilimumab, or pembrolizumab or nivolumab, respectively, as per the well-accepted ESMO and 
ASCO/NCCN guidelines and as noted below.28,29 
 
Dose modifications for cisplatin and gemcitabine are permitted as per standard of care. Thus, dose delays or split-dose 
administration of cisplatin for renal injury is permitted at investigator’s discretion. Dose reduction of gemcitabine up to 
25% or 750 mg/m2 is also permitted. 
 
For patients with CrCl between 50 – 60 mL/min, cisplatin should be administered as a split dose of 35 mg/m2, either on 
Days 1 & 2 or Days 1 & 8 of each cycle. 
 
Though the CKD-EPI equation may be used to determine study eligibility, the Cockroft-Gault equation will be used to 
determine any chemotherapy dosing as per pharmacy standard. 
 
Recommendations for Management of Immune-Related Adverse Events (irAEs) 
Immuno-oncology agents such as AGEN1884 and AGEN2034 are associated with irAEs. Early recognition and management 
of irAEs may mitigate severe toxicity. Investigators should also monitor subjects closely for potential irAEs, which may 
manifest after weeks of treatment, at the earliest. Such events may consist of persistent rash, diarrhea, colitis, autoimmune 
hepatitis, pneumonitis, encephalitis, arthritis, glomerulonephritis, cardiomyopathy, or uveitis and other inflammatory eye 
conditions. 
Management algorithms have been developed to assist investigators in assessing and managing the following groups of irAEs: 
gastrointestinal, pulmonary, dermatological, renal, hepatic, neurological, and endocrine, among others. 
AEs (both non-serious and serious) associated with drug exposure and consistent with an immune phenomenon may represent 
an immunologic etiology. These irAEs may be predicted based on the nature of the IMPs, its mechanism of action, and 
reported experience with immunotherapies that have a similar mechanism of action. An irAE can occur shortly after the first 
dose or several months after the last dose of treatment. Particular attention should be paid to AEs that may be suggestive of 
potential irAEs, as outlined below. 
irAEs are considered adverse events of special interest (AESIs) and should be reported to Agenus from the time 
of consent to participate in this trial up to at least 90 days (90-day safety follow-up visit) from last IMP 
administration. 
Dermatological irAEs 
 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and continue therapy per 
protocol. 
Dermatological irAE Management Algorithm 

Page 20 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Dermatological irAEs 
CTCAE Grade of Maculo- 
papular Rash 
Management 
Follow-up 
Grade 1 
Macules/papules covering <10% 
BSA with or without symptoms 
(e.g., pruritus, burning, tightness) 
Grade 2 
Macules/papules covering 
10-30% BSA with or without 
symptoms (e.g., pruritus, burning, 
tightness); limiting instrumental 
ADL; rash covering > 30% BSA 
with or without mild symptoms 
Symptomatic therapy (e.g., 
antihistamines, topical 
corticosteroids). 
Continue AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
If persists >1 to 2 weeks or recurs: 
Consider skin biopsy. 
Delay AGEN1884 and/or AGEN2034 
therapy. 
Consider 0.5-1 mg/kg/day 
methylprednisolone IV or oral equivalent. 
Once improving, taper corticosteroids over 
≥1 month; consider prophylactic antibiotics 
for opportunistic infections; and resume 
AGEN1884 therapy per protocol. 
If worsens: Treat as Grade 3-4. 
Grade 3 
Macules/papules covering >30% 
BSA with moderate or severe 
symptoms; limiting self-care 
ADL 
Delay or discontinue 
AGEN1884 and/or AGEN2034 
therapy per protocol. 
Consider skin biopsy. 
Dermatology 
consult 1-2 
mg/kg/day 
methylprednisolone IV or IV 
equivalent. 
If improves to Grade 1: Taper 
corticosteroids over ≥1 month; add 
prophylactic antibiotics for opportunistic 
infections. 
Resume AGEN1884 and/or AGEN2034 
therapy per protocol (unless AGEN1884 
and/or AGEN2034 was discontinued [vs. 
delayed] for the event). 
Abbreviations: ADL = activities of daily living; BSA = body surface area; CTCAE = Common Terminology 
Criteria for Adverse Events; irAE = immune-related adverse event; IV = intravenous. 
 
 
Gastrointestinal irAEs 
 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and 
continue therapy. Opiates/narcotics may mask symptoms of perforation. Infliximab should not be used in 
cases of perforation or sepsis 
 
Gastrointestinal irAEs Management Algorithm 
 
Gastrointestinal irAEs 
CTCAE Grade of Diarrhea/Colitis 
Management 
Follow-up 
Grade 1 
Diarrhea: 
Increase of <4 stools per day over 
baseline; mild increase in ostomy output 
compared to baseline 
Colitis: 
Continue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
Symptomatic treatment. 
Close monitoring for worsening 
symptoms. 
Educate subject to report worsening 
immediately. 
Consider symptomatic treatment 
including hydration, electrolyte 
replacement, dietary changes (e.g., 

Page 21 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Gastrointestinal irAEs 
CTCAE Grade of Diarrhea/Colitis 
Management 
Follow-up 
Asymptomatic; clinical or diagnostic 
observations only; intervention not 
indicated 
American Dietetic Association colitis 
diet), and loperamide. 
If worsens: Treat as Grade 2 or 3-4. 
Grade 2 
Diarrhea: 
Increase of 4-6 stools per day over 
baseline; moderate increase in ostomy 
output compared to baseline; limiting 
instrumental ADL 
Delay AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
Consider prompt 
diagnostic work-out and 
early start of 
corticosteroids 
If improves to Grade 1: Resume 
AGEN1884 and/or AGEN2034 therapy 
per protocol. 
If persists >5 to 7 days or recurs: 
0.5-1 mg/kg/day methylprednisolone or 
equivalent. 
Colitis: 
Abdominal pain; mucus or blood in stool 
Consider infliximab administration if no 
clear early response to corticosteroids. 
When symptoms improve to Grade 1, 
taper corticosteroids over ≥1 month; 
consider prophylactic antibiotics for 
opportunistic infections; resume 
AGEN1884 and/or AGEN2034 therapy 
per protocol. 
If worsens or persists >3 to 5 days with 
oral corticosteroids: Treat as Grade 3-4. 
Grade 3 
Diarrhea: 
Discontinue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
1-2 mg/kg/day 
methylprednisolone IV or 
equivalent. 
Add prophylactic 
antibiotics for 
opportunistic infections. 
Consider lower endoscopy. 
If improves: Continue corticosteroids 
until Grade 1, then taper over ≥1 month. 
Increase of ≥7 stools per day over 
baseline; hospitalization indicated; 
severe increase in ostomy output 
compared to baseline; limiting self-care 
ADL 
Colitis: 
If persists >3 to 5 days or earlier if no 
clear response or recurs after 
improvement: Add infliximab 5 mg/kg 
(if no contraindication). 
Note: Infliximab should not be used in 
cases of perforation or sepsis. 
Severe abdominal pain; peritoneal signs 
Grade 4 
Diarrhea: 
Life-threatening consequences; urgent 
intervention indicated 
Colitis: 
Life-threatening consequences; urgent 
intervention indicated 
Abbreviations: ADL = activities of daily living; CTCAE = Common Terminology Criteria for Adverse Events; irAE 
= immune-related adverse event; IV = intravenous. 
 
Pulmonary irAEs 
 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. Evaluate with imaging and pulmonary consultation 
 
Pulmonary irAE Management Algorithm 

Page 22 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
 
Pulmonary irAEs 
CTCAE Grade of 
Pneumonitis 
Management 
Follow-up 
Grade 1 
Radiographic changes only 
Grade 1 
Asymptomatic; clinical or 
diagnostic observations only, 
including radiographic 
changes 
Consider delay of 
AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
Monitor for symptoms every 
2-3 days. 
Consider pulmonary and 
infectious disease consults. 
Re-image every ≥3 weeks. 
If worsens: Treat as Grade 2 or 
Grade 3-4. 
Grade 2 
Symptomatic; medical 
intervention indicated; 
limiting instrumental ADL 
Delay AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
Pulmonary and infectious 
disease consults. 
Monitor symptoms daily; 
consider hospitalization. 
Re-image every 1-3 days. 
If improves: When symptoms return 
to near baseline, taper corticosteroids 
over ≥1 month, then resume 
AGEN1884 and/or AGEN2034 
therapy per protocol and consider 
prophylactic antibiotics. 
1 mg/kg/day 
methylprednisolone IV or 
oral equivalent. 
If not improving after 2 weeks or 
worsening: Treat as Grade 3-4. 
Consider bronchoscopy, lung 
biopsy. 
Grade 3 
Severe symptoms; limiting 
self-care ADL; oxygen 
indicated 
Grade 4 
Life-threatening respiratory 
compromise; urgent 
intervention indicated (e.g., 
tracheotomy or intubation) 
Discontinue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
Hospitalize. 
Pulmonary and infectious 
disease consults. 
2-4 mg/kg/day 
methylprednisolone IV or IV 
equivalent. 
Add prophylactic antibiotics 
for opportunistic infections. 
If improves to baseline: Taper 
corticosteroids over ≥6 weeks. 
If not improving after 48 hours or 
worsening: Add additional 
immunosuppression (e.g., infliximab, 
cyclophosphamide, IV 
immunoglobulin, mycophenolate 
mofetil). 
Consider bronchoscopy, lung 
biopsy. 
Abbreviations: ADL = activities of daily living; CTCAE = Common Terminology Criteria for Adverse Events; 
irAE = immune-related adverse event; IV = intravenous. 
 
Hepatic irAEs 

Page 23 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and 
continue therapy per protocol. Consider imaging for obstruction 
 
Hepatic irAE Management Algorithm 
 
Hepatic irAEs 
CTCAE Grade of 
Liver Test Elevation 
Management 
Follow-up 
Grade 1 
ALT/AST 
>ULN - 3.0 × IULN if baseline was 
normal; 1.5-3.0 × baseline if baseline was 
abnormal 
Bilirubin 
>ULN - 1.5 × IULN if baseline was 
normal; > 1.0-1.5 × baseline if baseline 
was abnormal 
Continue AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
Continue LFT monitoring per protocol. 
If worsens: Treat as Grade 2 or 
Grade 3-4. 
Grade 2 
Delay AGEN1884 and 
AGEN2034 therapy per 
protocol. 
Increase frequency of 
monitoring to every 3 days. 
If subject has concurrent AST 
or ALT >3 × IULN and total 
bilirubin >2 × IULN, 
discontinue AGEN1884 
therapy per protocol. 
If returns to baseline: Resume routine 
monitoring; resume AGEN1884 and 
AGEN2034 therapy per protocol. 
If elevations persist >5 to 7 days or 
worsen: 0.5-1 mg/kg/day 
methylprednisolone IV or oral equivalent. 
When LFT returns to Grade 1 or baseline, 
taper corticosteroids over ≥1 month, 
consider prophylactic antibiotics for 
opportunistic infections, and resume 
AGEN1884 and/or AGEN2034 therapy 
per protocol. 
ALT/AST 
>3.0-5.0 × IULN if baseline was normal; 
>3.0- 5.0 × baseline if baseline was 
abnormal 
Bilirubin 
>1.5-3.0 × IULN if baseline was normal; 
>1.5-3.0 × baseline if baseline was 
abnormal 
Grade 3 
ALT/AST 
Discontinue AGEN1884 
and/or AGEN2034 therapy per 
protocol. 
Increase frequency of 
monitoring to every 1-2 days. 
1-2 mg/kg/day 
methylprednisolone IV or oral 
equivalent.* 
Add prophylactic antibiotics 
for opportunistic infections. 
Consult gastroenterology. 
Consider obtaining MRI/CT 
scan of liver and liver biopsy if 
clinically warranted. 
If returns to Grade 2: Taper 
corticosteroids over ≥1 month. 
>5.0-20.0 × IULN if baseline was normal; 
>5.0-20.0 × baseline if baseline was 
abnormal 
Bilirubin 
>3.0-10.0 × IULN if baseline was normal; 
>3.0-10.0 × baseline if baseline was 
abnormal 
If does not improve in >3 to 5 days, 
worsens or rebounds: Add 
mycophenolate mofetil 1 g twice daily. If 
no response within an additional 3-5 days, 
consider other immunosuppressants per 
local guidelines. 
Grade 4 
ALT/AST 
>20.0 × IULN if baseline was normal; 
>20.0 × baseline if baseline was abnormal 
Bilirubin 
>10.0 × IULN if baseline was normal; 
>10.0 × baseline if baseline was abnormal 

Page 24 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CT = computed tomography; 
CTCAE = Common Terminology Criteria for Adverse Events; IULN = Institutional upper limit of institutional normal; 
irAE = immune-related adverse event; IV = intravenous; LFT = liver function test; MRI = magnetic resonance imaging; 
ULN = upper limit of normal. 
* The recommended starting dose for Grade 4 hepatitis is 2 mg/kg/day methylprednisolone IV. 
 
 
Endocrine irAEs 
 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and 
 
Endocrine irAE Management Algorithm 
 
Endocrine irAEs 
Endocrine Disorder 
Management 
Follow-up 
Asymptomatic TSH 
abnormality 
Continue AGEN1884 and/or AGEN2034 therapy per protocol. 
If TSH <0.5 × lower limit of normal (LLN) or TSH >2 × IULN, or 
consistently out of range in 2 subsequent measurements: Include 
free thyroxine at subsequent cycles as clinically indicated; consider 
endocrinology consult. 
Symptomatic 
endocrinopathy 
Evaluate endocrine function. 
Consider pituitary scan. 
Symptomatic with 
abnormal laboratory tests 
and/or pituitary scan: 
Delay AGEN1884 and/or 
AGEN2034 treatment per 
protocol; 1-2 mg/kg/day 
methylprednisolone IV or 
oral equivalent; initiate 
appropriate hormone 
therapy. 
No abnormal laboratory 
tests and/or pituitary MRI 
scan but symptoms persist: 
Repeat laboratory tests in 1- 
3 weeks, MRI in 1 month. 
Suspected thyroid 
dysfunction based on clinical 
symptoms. Check TSH and 
T4/T3. 
Low TSH and evaluated 
T4/T3 thyrotoxicosis likely 
due to thyroiditis 
1. Beta-blockers for 
If improves (with or without 
hormone replacement): Taper 
corticosteroids over ≥1 month and 
consider prophylactic antibiotics for 
opportunistic infections. 
Resume AGEN1884 and/or 
AGEN2034 therapy per protocol. 
Subjects with adrenal insufficiency 
may need to continue corticosteroids 
with mineralocorticoid component. 

Page 25 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Endocrine irAEs 
Endocrine Disorder 
Management 
Follow-up 
symptomatic patients 
2. Hold immunotherapy 
when CTCAE garde >=3 
3. Restart therapy when 
CTCAE grade <=2 
4. Check thyroid functions 
every 2-3 weeks 
5. If Graves disease, treat 
with methimazole or RAI/ 
surgery 
Once thyroid function test 
shows elevated TSH and low 
T4, diagnosis of 
hypothyroidism is made 
Elevated TSH, low T4/T3 
primary hypothyroidism 
1. Treat with levothyroxine 
2. Monitor TFTs every 6-8 
weeks until stable, then 6-12 
monthly 
Elevated TSH, low T4/T3 
primary hypothyroidism or 
low TSH, low T4/T3 central 
hypothyroidism 
1. Treat with levothyroxine 
2. Monitor TFTs every 6-8 
weeks until stable, then 6-12 
monthly 
Suspicion of adrenal crisis 
(e.g., severe dehydration, 
hypotension, shock out of 
proportion to current 
illness) 
Delay or discontinue AGEN1884 and/or AGEN2034 therapy per 
protocol. 
Rule out sepsis. 
Stress dose of IV corticosteroids with mineralocorticoid activity. 
IV fluids. 
Consult endocrinologist. 
If adrenal crisis ruled out, treat as above for symptomatic 
endocrinopathy. 
Abbreviations: irAE = immune-related adverse event; IULN = institutional upper limit of normal; IV = 
intravenous; LLN = lower limit of normal; MRI = magnetic resonance imaging; TSH = thyroid-stimulating 
hormone. 
 
Renal irAEs 

Page 26 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and 
continue therapy per protocol 
Renal irAE Management Algorithm 
 
Renal irAEs 
CTCAE Grade of 
Creatinine Increased 
Management 
Follow-up 
Grade 1 
>IULN - 1.5 × IULN 
Continue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
If returns to baseline: Resume 
routine creatinine monitoring per 
protocol. 
Monitor creatinine weekly. 
If worsens: Treat as Grade 2 or Grade 
3-4. 
Grade 2 
>1.5-3.0 × baseline; >1.5-3.0 × 
IULN 
Grade 3 
>3.0 × baseline; >3.0-6.0 × 
IULN 
Delay AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
Monitor creatinine every 
2-3 days. 
0.5-1.0 mg/kg/day 
methylprednisolone IV or 
oral equivalent. 
Consider renal biopsy. 
If returns to Grade 1: Taper 
corticosteroids over ≥1 month, 
consider prophylactic antibiotics for 
opportunistic infections, and resume 
AGEN1884 and/or AGEN2034 
therapy and routine creatinine 
monitoring per protocol. 
If elevations persist > 7 days or 
worsen: Treat as Grade 4. 
Grade 4 
Creatinine >6 × IULN 
Discontinue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
Monitor creatinine daily. 
If returns to Grade 1: Taper 
corticosteroids over ≥1 month and add 
prophylactic antibiotics for 
opportunistic infections. 
1.0-2.0 mg/kg/day 
methylprednisolone IV or 
IV equivalent. 
Consult nephrologist. 
Consider renal biopsy. 
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; irAE = immune-related adverse 
event; IULN = institutional upper limit of normal; IV = intravenous. 

Page 27 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Neurological irAEs 
Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and 
continue therapy per protocol 
 
Neurological irAE Management Algorithm 
 
Neurological irAEs 
CTCAE Grade of 
Nervous System Disorder, 
Other 
Management 
Follow-up 
Grade 1 
Asymptomatic or mild 
symptoms; clinical or diagnostic 
observations only; intervention 
not indicated 
Continue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
Continue to monitor subject. 
If worsens: Treat as Grade 2 or Grade 3 
4. 
Grade 2 
Moderate; minimal, local or 
noninvasive intervention 
indicated; limiting age- 
appropriate instrumental ADL 
Delay AGEN1884 and/or 
AGEN2034 therapy per 
protocol. 
Treat symptoms per local 
guidelines. 
Consider 0.5- 
1.0 mg/kg/day 
methylprednisolone IV or 
oral equivalent. 
If returns to baseline: Resume 
AGEN1884 therapy per protocol. 
If worsens: Treat as Grade 3-4. 
Grade 3 
Severe or medically significant 
but not immediately life- 
threatening; hospitalization or 
prolongation of existing 
hospitalization indicated; 
limiting self-care ADL 
Grade 4 
Life-threatening consequences; 
urgent intervention indicated 
Discontinue AGEN1884 
and/or AGEN2034 therapy 
per protocol. 
Obtain neurology consult. 
Treat symptoms per local 
guidelines. 
1.0-2.0 mg/kg/day 
methylprednisolone IV or 
IV equivalent. 
Add prophylactic 
antibiotics for opportunistic 
infections. 
If improves to Grade 2: Taper 
corticosteroids over ≥1 month. 
If worsens or atypical presentation: 
Consider IV immunoglobulin or other 
immunosuppressive therapies per local 
guidelines. 

Page 28 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
4.5 
Study Safety Review 
4.5.1 Study Safety Review Committee 
The study safety review committee consists of the Mays Cancer Center DSMB and the principal 
investigator or designated research staff treating subjects on study. Safety will be monitored with 
biweekly study team calls and reviewed during safety committee meetings. 
4.5.2 Dose-Limiting Toxicities 
For the purposes of safety evaluation during the safety run-in portion of the study, subjects will be 
monitored for DLTs during the first cycle of chemotherapy plus immunotherapy agents. However, should 
AEs meeting DLT criteria occur outside this DLT evaluation period, the safety review committee will 
evaluate alternative doses or administration methods if warranted. Any subject who develops a DLT will 
be removed from study treatment and followed for safety. The subject once removed from study treatment 
may proceed to radical cystectomy, in which case he/she would remain evaluable for the primary 
endpoint if he/she meets evaluability criteria as set forth. 
4.5.2.1 Definition of Dose Limiting Toxicity 
DLT, as defined below, will be evaluated throughout concurrent therapy with cisplatin, gemcitabine, 
AGEN1884 and AGEN2034. Toxicity that is clearly and directly related to the primary disease or to 
another etiology is excluded from this definition. The following drug related AEs will be DLTs: 
Any grade 5 AEs 
Immune Related AEs (irAEs) 
1. Grade 4 immune-related AEs 
2. Any grade 3 irAE that does not resolve to ≤ Grade 1 or to baseline with immunosuppressive 
therapy within 3 weeks of its onset 
3. Any grade 3 central nervous system (CNS)-related irAE regardless of duration, or reversibility 
Any Grade 4 non-hematologic, non-laboratory AEs will be considered DLTs with the exception of 
isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical sequelae and 
are corrected with supplementation/appropriate management within 72 hours of their onset 
Grade 4 hematologic AEs with following exceptions: 
1. Grade 4 neutropenia that is not associated with fever or systemic infection that improves by at 
least 1 grade within 3 days. Grade 4 febrile neutropenia will be a DLT regardless of duration 
or reversibility. 
2. Grade 4 lymphopenia 
3. Grade 4 thrombocytopenia that is not associated with clinically significant bleeding that 
requires medical intervention, and improves by at least 1 grade within 3 days 
4. Other Grade 4 hematologic AEs that last less than 7 days 
The definition of DLT excludes the following other conditions: 
1. Grade 3 fatigue lasting ≤ 7 days 
2. Grade 3 endocrine disorder (thyroid, pituitary, and/or adrenal insufficiency) that is managed 
with or without systemic corticosteroid therapy and/or hormone replacement therapy and the 
subject is asymptomatic 
3. Grade 3 infusion-related reaction (first occurrence and in the absence of steroid prophylaxis) 
that resolves within 6 hours with appropriate clinical management 

Page 29 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
4. Grade 3 flu-like symptoms or fever lasting <6 hours, which are controlled with medical 
management 
Immune-related AEs are defined as AEs of an immune nature (i.e., inflammatory) in the absence of a 
clear alternative etiology. In the absence of a clinically significant abnormality, repeat laboratory testing 
will be conducted to confirm significant laboratory findings prior to designation as a DLT. 
All DLTs will be assessed by the investigator using National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0. 
4.5.2.2 Stopping Early Rules for Enrollment Based on Toxicities 
DLTs for either investigational agent tested will stop the protocol. If any of the investigational agents 
cannot be continued, the patient will come off all study treatment and proceed as per standard of care. 
In addition, the Mays Cancer Center DSMB 2 in conjunction with the PI will review the safety of all 
study subjects. Should any AEs be consistent with DLTs (e.g., from immune-related toxicities), they will 
be evaluated for relatedness to study agents. Should AEs meeting DLT criteria occur beyond the defined 
DLT evaluation period, the DSMB should be notified by the PI of the study to evaluate alternative doses 
or administration methods. 
If there is a subject death within 30 days of any study drug administration for reasons not related to the 
subject’s disease recurrence, the trial will be put on hold to accrual and treatment will be held for subjects 
on study until an appropriate evaluation of the cause of death is determined, unless the death is from 
accidental trauma. If the PI determines that the death is related to study treatment, a study amendment 
and/or other corrective action plan will be established. If the death is determined not to be related to study 
treatment, the study will re-open to accrual and subjects on study will resume treatment. 
4.5.2.3 Prior and Other Concomitant Therapy 
Allowed and disallowed prior and concomitant therapies are described under inclusion and exclusion 
criteria. Investigators are permitted to use any SOC agents to mitigate any adverse events related to SOC 
chemotherapy, and any SOC agents used to mitigate adverse events related to nivolumab or 
pembrolizumab, or ipilimumab for AGEN2034 or AGEN1884 adverse events, respectively. The principal 
investigator has ultimate discretion to grant exceptions to the use of otherwise excluded agents in 
mitigation of adverse events. 
4.6 
Study Schedule 
Screening Visit 
This will occur within 30 days of study enrollment. 
Pretreatment: Week -1 to 0 
All final clinical assessments are made and initial screening laboratory and imaging studies are 
accomplished and recorded. The treatment consent is signed. Baseline imaging and laboratory studies 
must be accomplished within 45 days of the first treatment on this protocol. Blood specimens will be 
drawn for the research repository. 
Treatment and Evaluation Period: Weeks 1 to 15 
Subjects receive up to 4 cycles of neoadjuvant cisplatin-gemcitabine chemotherapy plus AGEN2304 and 
AGEN1884, which takes around 12 weeks. Imaging is done after 2 cycles of therapy, prior to cycle 3, to 
rule out radiographic progression, as is SOC. After completion of the planned 4 cycles of neoadjuvant 
therapy, subjects will proceed to radical cystectomy with an interval of no greater than 10 weeks from the 
last dose of neoadjuvant therapy. The surgical pathology specimens will then be used to evaluate for the 
primary outcome of pathologic tumor downstaging. 

Page 30 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Research phlebotomies will be performed at baseline and on day 1 of cycle 3 at time of 
cystectomy, and at the first visit in the follow-up timeframe. 
Follow-up Period: Weeks 15 to 52 
Subjects will be followed every 3 weeks during experimental therapies (typically being seen at treatment 
cycles), then every 3 months after the end of treatment visit for 1 year from the initiation of experimental 
treatments, and then quarterly but no less than for 1 year from initiation of treatment. Blood specimens 
and urine collection will be drawn for the repository during the first 3-month follow-up. 
End-of-Treatment Visit 
Survival Follow-up 
Patients are followed in clinic through year 1 after treatment as defined above. Thereafter, they will be 
seen based on their clinical stability but no less than every 6 months for a total of 2 years. After 1 year, a 
telephone call can be substituted for a clinic visit for stable patients. 
4.7 
Demographics and Screening Procedures 
Demographics and Medical/Cancer History. These are recorded in a HIPAA compliant manner per 
Mays Cancer Center protocols. 
Eastern Cooperative Oncology Group Performance Status. Patients must have an ECOG performance 
status of 0-1 within the screening period to be eligible. 
4.8 
Correlative Biology 
The goal of this repository is to capture immune profiles of genitourinary cancer patients and tumors 
using whole blood, fat, urine, and tissue. These immune profiles will be critical to understanding the 
importance of immunity in regulating cancer, including a specific project to determine the ability of the 
AGEN1884 and AGEN2034 to modulate immune profiles. The specimens will also be stored for 
potential use in additional studies in the future. Currently our focus is largely related to bladder cancer. 
 
Studies of blood material 
Blood specimens will be banked for future research. Blood samples (30mLs at each visit) will drawn at 
the time points listed in the Study Calendar. 
 
Studies of tumor material 
Surgical tumor specimens remaining from original TURBT and radical cystectomy banked for future 
research. 
4.9 Disease Assessments 
4.9.1 Imaging 
Imaging is done using standard equipment and read by a radiologist. CT, MRI or CT/PET fusion are 
acceptable. 
4.9.2 Pathologic Response Criterion 
The primary efficacy assessment will be pCR rate (defined as no residual tumor in bladder and lymph 
nodes on resected specimen). Surgery should be performed within 6 weeks after completing up to 4 
cycles (last dose) of neoadjuvant therapy, but can be done up to 10 weeks after treatment ends to be 
evaluable. Otherwise this patient must be replaced for response evaluation. Pelvic lymph node dissection 

Page 31 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
should include a minimum standard lymph node dissection, which includes bilateral obturator, external 
iliac, and internal iliac lymph nodes. For histologic assessment, all tumor and lymph node tissue should 
be sectioned at 0.5 centimeter intervals. The specimen should be sampled as follows: at least 1 section 
per centimeter of primary tumor, or all tumor if less than 5 cm, and entirety of all lymph nodes 
submitted. The percentage of viable tumor cells in sections containing tumor should be evaluated. For 
assessments of pathological response, at least 1 section per centimeter of the tumor should be evaluated 
for all tumor and lymph node samples. A minimum of 5 slides should be evaluated, even if tumor 
diameter is < 5cm. 

Page 32 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
 
4.10 
Safety Assessments 
Vital Signs are aural temperature, respiratory rate, peripheral pulse and blood pressure. 
Physical Examination is done per SOC. 
Clinical Laboratory Assessments and Urinalysis are done per SOC. 
Pregnancy Test is per SOC. 
Concomitant Medications are recorded by study personnel. 
Disease Recurrence, Secondary Cancer, Elective Surgery, and Death are recorded per routine Mays Cancer Center routine procedures. 
Table 2, Study Calendar 
 
Baseline 
C1D1 
(Day 1) 
C1D8 
(Day 8 
±2 days) 
 
C2D1 
(Day 22 
±2 days) 
C2D8 
(Day 29 
±2 days) 
C3D1 
(Day 43 
±2 days) 
C3D8 
(Day 50 
±2 days) 
C4D1 
(Day 64 
±2 days) 
C4D8 
(Day 71 
±2 days) 
End of 
Treatment 
(Day 85 ±5 
days) 
Cystectomy 
(within 10 
weeks of last 
chemo) 
Follow Up 
(q3 months 
post- 
Cystectomy)
+/- 7 days 
AGEN1884 Infusion 
X 
X 
AGEN2034 Infusion 
X 
X 
X 
X 
Cisplatin 70mg/m2 
Infusion* 
X 
X 
X 
X 
Gemcitabine 
1000mg/m2 Infusion 
X 
X 
X 
X 
X 
X 
X 
X 
History & Physical 
X 
X 
X 
X 
X 
X 
X 
Vital Signs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
ECOG 
X 
X 
X 
X 
X 
X 
NYHA 
X 
Informed Consent 
X 
CBC, CMP 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TSH 
X 
X 
X 
X 
X 
X 
AM cortisol 
X 
Urine collection 
X 
X 
X 
X^ 
24 hr urine CrCl 
X 
Imaging (CT Chest 
and CT or MRI A/P) 
X 
X 
X 
Serum Pregnancy Test 
X 
X 
X 
X 
X 

Page 33 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
 
Baseline 
C1D1 
(Day 1) 
C1D8 
(Day 8) 
 
C2D1 
(Day 22) 
C2D8 
(Day 29) 
C3D1 
(Day 43) 
C3D8 
(Day 50) 
C4D1 
(Day 64) 
C4D8 
(Day 71) 
End of 
Treatment 
Cystectomy 
(within 10 
weeks of last 
chemo) 
Follow Up 
(q3 months 
post-EOT) 
+/- 7 days 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Survival Assessment 
X# 
Tumor pathologic 
assessment 
X 
X 
Concurrent 
medication review 
X 
X 
X 
X 
X 
X 
Tumor tissue 
collection (archival or 
fresh) 
X 
X 
Research Blood draw 
X 
X 
X 
X^ 
^ denotes sample is only required at first of the 3-month follow up visits 
# denotes follow up to occur every 3 months for first year then as per section 4.6  
Note: Imaging performed after treatment has been initiated will be done after cycle 2 is administered and before cycle 3. 

Page 34 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
5. STATISTICAL CONSIDERATIONS 
5.1 Study Design/Endpoints 
Primary Endpoint(s): 
• 
pT0 or pCR, defined as eradication of all tumor from resected bladder and lymph node tissue, 
following neoadjuvant chemotherapy 
Secondary Endpoint(s): 
• 
Toxicity per CTCAE v5.0 
• 
Pathologic downstaging to <T2 
• 
Completion of surgery 
• 
Progression-free survival at 1 year 
Exploratory Endpoint(s): 
• 
Correlative immune outcomes 
The study begins with enrolment of 3 patients who will be followed for DLTs that occur within the first 
cycle of treatment. If no patients experience a DLT during the window, further accrual as per the Simon 
two-stage design below will proceed. If one DLT is observed in the first 3 patients during the window, an 
additional 3 patients will be enrolled. If <2 DLTs occur in the first 6 patients during the window, further 
accrual to the study will proceed. If >2 DLTs occur in the first 6 patients during the window, the study 
results will be assessed if substantial modifications to the protocol would be required. 
For the overall study, we will utilize a modified Simon two-stage design employing a minmax design, 
enrolling 17 patients in stage I and subsequently 19 more patients in stage II if early termination criteria 
are not met. There are early termination criteria for futility. To be evaluable for the primary endpoint, 
patients must have received at least two cycles of neoadjuvant therapy and undergone cystectomy. Using 
a historical pCR rate of 0.25 as the null hypothesis, we will seek to demonstrate a rate of 0.45. The 
reported pCR rates to cisplatin-based neoadjuvant chemotherapy vary widely, ranging from 15-41%4,23-26. 
We have chosen a rate of 25% based on the pCR rate for GC from a large, recent cross-sectional analysis 
of 332 patients who received neoadjuvant chemotherapy prior to cystectomy.26 We will submit 17 patients 
to treatment and fail to reject the null hypothesis and terminate the study unless at least 5/17 pCRs are 
observed. If at least 5 pCRs are observed, we will submit an additional 19 patients to treatment. If at least 
14/36 pCRs are observed we will reject the null hypothesis in favor of the sought improvement in success 
rate. This modified Simon two-stage design yields a type I error rate of 0.044 and power of 0.8 when the 
true response rate is 0.45. 
Of note, if the therapy is found not to meet criteria for continuation to Stage 2 of the Simon two-stage 
design based on pCR rate, but vastly improves the downstaging to <pT2 rate, a discussion will be 
conducted among investigators and the sponsor to consider amending the protocol to continue enrollment 
with an alternate primary endpoint of <pT2 rate. The advantages and disadvantages of such an 
amendment, along with ethical concerns would be addressed prior to re-opening the study. 
The number screened, the number of screen failures by reason, the number enrolled, and the number lost 
to follow-up reason will be tabulated. The Simon two-stage design results will be descriptively 
summarized. Secondary end points will be descriptively summarized. Progression free survival will be 
described with a graphic of the Kaplan-Meier curve, the median time to progression, and a 95% 
confidence interval for the median time to progression. Tabular summaries, graphics, and the median time 
to progression will be provided with R30. 

Page 35 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
 
 
 
 
6. DATA COLLECTION 
All quantitative study data will be entered into Research Electronic Data Capture (REDCap), a secure 
web-based database, which the research staff is well trained to use and has been studied for many other 
clinical trials. 
7. DATA REPORTING / REGULATORY REQUIREMENTS 
Data and Safety Monitoring Oversight 
A Data and Safety Monitoring Plan is required for all individual protocols conducted at MAYS CANCER 
CENTER. All protocols conducted at MAYS CANCER CENTER are covered under the auspices of the 
MAYS CANCER CENTER Institutional Data Safety Monitoring Plan (DSMP). 
 
The MAYS CANCER CENTER Institutional DSMP global policies provide individual trials with: 
• 
institutional policies and procedures for institutional data safety and monitoring, 
• 
an institutional guide to follow, 
• 
monitoring of protocol accrual by the MAYS CANCER CENTER Protocol Review Committee, 
• 
review of study forms and orders by the Forms Committee, 
• 
tools for monitoring safety events, 
• 
independent monitoring and source data verification by the MAYS CANCER CENTER QA 
Monitor/Auditor 
• 
monitoring of UPIRSO’s by the Director of Quality Assurance and DSMC, 
• 
determining level of risk (Priority of Audit Level Score – PALS), 
• 
oversight by the Data Safety Monitoring Committee (DSMC), and 
• 
verification of protocol adherence via annual audit for all Investigator Initiated Studies by the 
MAYS CANCER CENTER Quality Assurance Division. 
 
Monitoring Progress and Safety 
Due to the risks associated with participation in this protocol, the MAYS CANCER CENTER DSMB in 
conjunction with the Principal Investigator will perform assessment of adverse events, adverse event trends 
and treatment effects on this study. The MAYS CANCER CENTER DSMB acts as an independent Data 
Safety Monitoring Board (DSMB) for IIS conducted at MAYS CANCER CENTER. The MAYS CANCER 
CENTER DSMB will monitor data throughout the duration of a study to determine if continuation of the 
study is appropriate scientifically and ethically. An additional layer of review is provided by the MAYS 
CANCER CENTER Data Safety Monitoring Committee (DSMC) who will review DSMB quarterly 
reports. 
 
Baseline events and adverse events will be captured using the MAYS CANCER CENTER Master Adverse 
Events Document for each patient using CTCAE V. 5.0 for the grading and attribution of adverse events. 
Usage of the MAYS CANCER CENTER Master Adverse Events Document centrally documents: 
• 
the event and grades the seriousness of the event, 
• 
if the event was a change from baseline, 
• 
the determination of the relationship between the event and study intervention, 
• 
if the event was part of the normal disease process, and 
• 
what actions were taken as a result of the event. 

Page 36 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Safety Definitions: 
For this study, the following safety definitions will be applicable: 
 
Adverse Event Definition: An adverse event (AE) is defined as any untoward or unfavorable medical 
occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or 
laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the 
research, whether or not considered related to the subject’s participation in the research. For this study, all 
adverse events will be documented starting with administration of the first investigational agent. 
 
Serious Adverse Event Definition: is any adverse event that: 
1. results in death; 
2. is life-threatening (places the subject at immediate risk of death from the event as it occurred); 
3. results in inpatient hospitalization or prolongation of existing hospitalization; 
4. results in a persistent or significant disability/incapacity; 
5. results in a congenital anomaly/birth defect; or 
6. based upon appropriate medical judgment, may jeopardize the subject’s health and may require 
medical or surgical intervention to prevent one of the other outcomes listed in this definition 
 
Unanticipated Problems Involving Risks to Subjects or Others Definition: Unanticipated problem 
involving risk to subjects or others includes any incident, experience or outcome that meets all of the 
following criteria: 
 
A. unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are 
described in the protocol-related documents, such as the IRB-approved research protocol and 
informed consent document; and (b) the characteristics of the subject population being studied 
(note: the unfounded classification of a serious adverse event as “anticipated” constitutes serious 
non-compliance); 
B. definitely related or probably related to participation in the research; and 
C. suggests that the research places subjects or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized 
 
Reporting Requirements 
For this study, the Master Adverse Events Documents collected on patients for this protocol will be 
reviewed by the Principal Investigator to determine if a serious safety problem has emerged that result in a 
change or early termination of a protocol such as: 
• 
dose modification, 
• 
suspending enrollment due to safety or efficacy, or 
• 
termination of the study due to a significant change in risks or benefits. 
 
The PI will provide the DSMB with a summary of adverse events and serious adverse events on a quarterly 
basis for discussion and review during their meetings. The first report will be due to the DSMB the quarter 
immediately following enrollment of the first subject. The DSMB meets in March, June, September and 
December, however will additionally review events and issues on an as needed basis. 
 
The PI (or designee) is responsible for notifying sub-investigators regarding DSMB recommendations to 
modify the dosage (dose escalate, dose decrease) or expand the dosage to ensure that subsequent subjects 
are treated at the currently approved dose level. Changes to dosing should be approved by the DSMB 

Page 37 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
prior to proceeding. To further ensure safety, the study coordinator will notify the Investigative Drug 
Section and confer with the study PI on Cycle 1 Day 1 dosing orders to ensure the study drug dose 
escalations or de-escalation have has been updated correctly. 
 
Dose modifications for AGEN1884 and/or AGEN2034 are as set forth in dose escalation/de-escalation 
rules above. 
 
Toxicities related to AGEN1884 and AGEN2034 are managed per the SOC for toxicities related to the 
similar agents ipilimumab and pembrolizumab, respectively. Management guidelines are published by 
ASCO/NCCN.29 
 
For SOC chemotherapy, toxicities, dose adjustments and treatment delays are managed at investigator 
discretion, consistent with the guidelines for SOC. 
 
Discontinuation of Therapy 
Treatment with specific investigational agents should be discontinued if 1 or more of the following occur: 
• 
DLT occurrence or other unacceptable study drug–related AE (based on the investigator’s clinical 
decision that the subject is unable to tolerate therapy). 
• 
Recurrence of disease 
• 
Study discontinuation criterion met 
• 
Investigator decision 
• 
Subject nonadherence to protocol 
 
Subjects who discontinue therapy prior to recurrence will continue to undergo complete disease 
assessments according to SOC for up to 1 year after first study drug administration, or until a criterion for 
discontinuation of disease assessment is met. If subjects are clinically stable at 6 months, imaging 
frequency will be decreased to every 12 weeks until 1 year. Subjects will be followed for safety for 
≥30 days following the last administration of investigational agents. 
 
Discontinuation from Disease Assessment 
Subjects will be discontinued from disease evaluation if 1 or more of the following occur: 
• 
Recurrence of disease 
• 
Study discontinuation criterion met 
• 
Nonadherence with protocol. 
 
Discontinuation from Study 
Subjects will be discontinued from the study for 1 or more of the following: 
• 
Withdrawal of consent 
• 
Loss to follow-up 
• 
Death 
• 
Subject nonadherence. 
• 
Completion of full study period 
• 
Administrative study closure 
 
Premature Discontinuation of the Trial 
The entire trial may be discontinued prematurely in the event of any of the following: 

Page 38 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
• 
New information leading to unfavorable risk-benefit judgement of the study treatment due to 
(e.g.): 
− 
Occurrence of significant adverse reactions. 
− 
Other unfavorable safety findings. Note: Evidence of inefficacy may arise from this trial 
or from other trials, and unfavorable safety findings may arise from clinical or non- 
clinical examinations (e.g., toxicology). 
• 
Sponsor’s decision that continuation of the trial is unjustifiable for medical or ethical reasons 
• 
Poor enrollment of subjects, making completion of the trial within an acceptable timeframe 
unlikely 
• 
Discontinuation of development of the study treatment 
 
Health authorities and Independent Ethics Committees (IECs)/Institutional Review Boards (IRBs) will be 
informed about trial discontinuation in accordance with applicable regulations. 
The entire trial may be terminated or suspended upon request of health authorities and/or by the DSMB. 
 
As per the MAYS CANCER CENTER DSMP, any protocol modifications, problematic safety reports, 
unanticipated problems, and suspension or early termination of a trial must be reported to the DSMB and 
all members of the research team. Furthermore, the PI of this study will promptly notify all study affiliates, 
the UT HEALTH IRB, the MAYS CANCER CENTER DSMB, and the FDA via a FDA Form 3500Aa 
written IND safety report of any adverse events that are either serious and/or unexpected. Suspension and 
early termination of a trial must also be reported immediately to the Director of Quality Assurance who 
will promptly notify the UT HEALTH IRB. 
 
The PI will review the Master Adverse Events documents to determine the significance of the reported 
events and will provide findings using the Investigator Initiated Study Quarterly DSMB Report Form on a 
quarterly basis with the DSMB. The DSMB will review the information provided by the PI and report to 
the MAYS CANCER CENTER DSMB on a quarterly basis, unless an emergent issue has been identified. 
The Investigator Initiated Study Quarterly DSMB Report Form includes information on adverse events, 
current dose levels, number of patients enrolled, significant toxicities per the protocol, patient status 
(morbidity and mortality) dose adjustments with observed response, and any interim findings. Any trend 
consisting of three or more of the same event will be reported to the MAYS CANCER CENTER DSMB 
for independent review outside of the quarterly reporting cycle, which begins the quarter after the first 
patient is enrolled on the protocol. The DSMB will also provide its findings to the MAYS CANCER 
CENTER’s Regulatory Affairs Division so that it may be provided to the UT HEALTH IRB with the 
protocol’s annual progress report. Conflict of interest is avoided by the independent reviews of the MAYS 
CANCER CENTER DSMB, MAYS CANCER CENTER DSMC, and by ongoing independent review of 
UPIRSO trends by the Director of Quality Assurance. 
 
All SAE and UPRISO’s will be reported following MAYS CANCER CENTER, UT HEALTH institutional 
and FDA guidelines. 
UT HEALTH SAE/UPRISO REPORTING REQUIREMENTS For IIS that the PI holds the IND 
Type Event 
Report to 
Timeframe 
All AE, SAE and UPIRSO 
Regulatory Affairs and DQA 
ASAP 
All AE, SAE and UPIRSO 
FDA on form 3500A 
within 7 calendar days by 
telephone and 15 calendar days 
using the Form 3500A 
SAE 
PI at UT HEALTH 
within 24 hours 

Page 39 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
SAE 
UT HEALTH IRB 
Annually 
UPIRSO - all 
PI at UT HEALTH 
within 24 hours 
UPIRSO - all 
FDA 
within 7 days 
UPIRSO - life threatening 
UT HEALTH IRB/UT 
HEALTH OCR 
within 48 hours 
UPIRSO - non-life threatening 
UT HEALTH IRB/UT 
HEALTH OCR 
within 7 days 
 
AE’s and SAE events that occur during clinical trials with or without an Investigational New Drug (IND) 
application are mandatory reports submitted to FDA via Medwatch FDA F3500A within 15 days for events 
that have at least a possible relationship with the drug. 
 
Additionally, reporting to Agenus for AE’s, AESI and SAE’s should follow reporting requirements as 
outlined in the external reporting section. 
 
Assuring Compliance with Protocol and Data Accuracy 
As with all studies conducted at MAYS CANCER CENTER, the PI has ultimate responsibility for ensuring 
protocol compliance, data accuracy/integrity and responding to recommendations that emanate from 
monitoring activities. Protocol compliance, data accuracy and reporting of events is further ensured by an 
annual audit conducted by the Data Safety Officer, whose audit report is shared with the PI, the research 
team, and will be reviewed by the MAYS CANCER CENTER DSMC. 
 
MAYS CANCER CENTER DSMB Membership 
The MAYS CANCER CENTER has a primary set of members consisting of UT HEALTH faculty and 
staff. This Protocol will utilize the Mays CC DSMB for solid tumor studies. 
 
As per NCI guidelines and to eliminate conflict of interest (financial, intellectual, professional, or regulatory 
in nature), the MAYS CANCER CENTER DSMB specific to this study will not treat patients on this 
protocol. Usage of the DSMB specific to the histology has been created to ensure that oncology experts in 
that histology are represented on the DSMB assembled for this protocol, but may be expanded, at the PI’s 
discretion, to include other members which may include: 
• 
experts in the fields of medicine and science that are applicable to the study (if not currently 
represented on the DSMB), 
• 
statistical experts, 
• 
lay representatives, 
• 
multidisciplinary representation, from relevant specialties including experts such as bioethicists, 
biostatisticians and basic scientists, and 
• 
others who can offer an unbiased assessment of the study progress. 
Additional or alternate membership of in the DSMB is selected by the DSMC chair, in conjunction with 
the PI of this protocol. 
 
MAYS CANCER CENTER DSMB Charter and Responsibilities 
 
The MAYS CANCER CENTER DSMB will provide information on the membership composition, 
including qualifications and experience to both the UT HEALTH IRB and MAYS CANCER CENTER 
PRC for review. The MAYS CANCER CENTER DSMB for this study will act as an independent advisory 
board to the PI and will report its findings and recommendations to the PI, the UT HEALTH IRB and the 
MAYS CANCER CENTER DSMB. MAYS CANCER CENTER DSMB reports will utilize the 
Investigator Initiated Study Quarterly DSMB Report Form and meetings will occur on a monthly basis. 

Page 40 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
Once the protocol is activated, if not already established elsewhere in the protocol the MAYS CANCER 
CENTER DSMB will establish and provide: 
• 
procedures for maintaining confidentiality; 
• 
statistical procedures including monitoring guidelines, which will be used to monitor the identified 
primary, secondary, and safety outcome variables; 
• 
consider factors external to the study when relevant information becomes available, such as 
scientific or therapeutic developments that may have an impact on the safety of the participants or 
the ethics of the study; 
• 
plans for changing frequency of interim analysis as well as procedures for recommending protocol 
changes; 
• 
recommendation of dose escalation, MTD recommendation of early termination based on efficacy 
results, or expanding the cohort; 
• 
recommendation of termination due to unfavorable benefit-to-risk or inability to answer study 
questions; 
• 
recommendation of continuation of ongoing studies; 
• 
recommend modification of sample sizes based on ongoing assessment of event rates; and 
review of final results and publications. 
 
EXTERNAL REPORTING REQUIREMENTS 
 
The Investigator will report all adverse reactions to the FDA according to 21 Code of Federal Regulations 
(CFR) 312.32 and according to applicable regulatory authorities and institutional ethics committees. 
 
For SAE’s the investigator must notify Agenus immediately (i.e., ≤24 hours after becoming aware) via e- 
mail and later send the Medwatch FDA F3500A used for submission to FDA by fax, or e-mail. 
 
By electronic media (Adverse.Events@Agenusbio.com) 
or 
Paper (Fax: +1-781-674-4261). 
 
 
For the following SAEs the reporting period to Agenus or designee is ≤ 8 hours after becoming aware of 
the event: 
 
• drug- death related to AGEN2034 or AGEN1884 after less than 30 days of dosing 
 
• AGEN2034 or AGEN1884-related life-threatening event. 
 
 
Reporting procedures and timelines are the same for any new information on a previously reported SAE 
(= follow-up). 
 
Pregnancy and in Utero Drug Exposure 
Only pregnancies considered by the investigator as related to study treatment (e.g., resulting from a drug 
interaction with a contraceptive medication) are considered as AEs. 

Page 41 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
However, all pregnancies with an estimated conception date from first administration to 30-days after the 
participant’s last investigational treatment/intervention must be recorded. 
 
The same rule applies to pregnancies in female subjects and in female partners of male subjects. The 
investigator must notify Agenus or designee in an expedited manner of any pregnancy using the same 
process as described for SAE reporting. 
 
Investigator must actively follow up, document, and report the outcome of these pregnancies, even if 
subjects are withdrawn from the trial. A separate consent will be obtained for follow-up of these subjects. 
 
The investigator must notify Agenus or designee of these outcomes and in case of abnormal outcome, the 
SAE report form if the subject sustains an event and the parent-child/fetus AE report form when the 
child/fetus sustains an event). 
 
Any abnormal outcome must be reported in an expedited manner, using the same process as described for 
SAE reporting, whereas normal outcomes must be reported within 45 days from delivery. 
 
In the event of a pregnancy in a subject occurring during the course of the trial, the subject must be 
discontinued from trial medication immediately. The Agenus or designee must be notified without delay 
and the subject must be followed as described above. 

Page 42 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
8. References 
1. 
Raghavan D, Shipley WU, Garnick MB, et al: Biology and management of bladder 
cancer. 322:1129-1138, 1990 
2. 
Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus 
cystectomy compared with cystectomy alone for locally advanced bladder cancer. 349:859-866, 2003 
3. 
Choueiri TK, Jacobus S, Bellmunt J, et al: Neoadjuvant dose-dense methotrexate, 
vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: 
pathologic, radiologic, and biomarker correlates. J Clin Oncol 32:1889-94, 2014 
4. 
Plimack ER, Hoffman-Censits JH, Viterbo R, et al: Accelerated methotrexate, 
vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle- 
invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and 
toxicity. 32:1895, 2014 
5. 
Network NJNCCN: NCCN clinical practice guidelines in oncology: bladder cancer 
version 3.2018. 3:2108, 2018 
6. 
Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in 
previously untreated patients with metastatic urothelial cancer. 15:3394-3398, 1997 
7. 
von der Maase H, Hansen S, Roberts J, et al: Gemcitabine and cisplatin versus 
methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a 
large, randomized, multinational, multicenter, phase III study. 18:3068-3077, 2000 
8. 
von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a 
randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus 
cisplatin in patients with bladder cancer. 23:4602-4608, 2005 
9. 
Huo J, Ray-Zack MD, Shan Y, et al: Discerning Patterns and Quality of Neoadjuvant 
Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. 2018 
10. 
Soto Parra H, Cavina R, Latteri F, et al: Three-week versus four-week schedule of 
cisplatin and gemcitabine: results of a randomized phase II study. 13:1080-1086, 2002 
11. 
Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in 
human cancer. Nature 500:415-21, 2013 
12. 
Topalian SL, Taube JM, Anders RA, et al: Mechanism-driven biomarkers to guide 
immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275-87, 2016 
13. 
Paterson AM, Brown KE, Keir ME, et al: The programmed death-1 ligand 1:b7-1 
pathway restrains diabetogenic effector T cells in vivo. J Immunol 187:1097-105, 2011 
14. 
Topalian SL, Drake CG, Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to 
activate anti-tumor immunity. Curr Opin Immunol 24:207-12, 2012 
15. 
Rosenberg J, Sharma P, de Braud F, et al: LBA32 Nivolumab (N) alone or in 
combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial 
carcinoma (mUC), including the nivolumab 1 mg/kg+ ipilimumab 3 mg/kg expansion from CheckMate 
032. 29:mdy424. 038, 2018 
16. 
Motzer RJ, Tannir NM, McDermott DF, et al: Nivolumab plus ipilimumab versus 
sunitinib in advanced renal-cell carcinoma. 378:1277-1290, 2018 
17. 
Antonia SJ, López-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus 
ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 
trial. 17:883-895, 2016 
18. 
Hellmann MD, Ciuleanu T-E, Pluzanski A, et al: Nivolumab plus ipilimumab in lung 
cancer with a high tumor mutational burden. 2018 
19. 
Langer CJ, Gadgeel SM, Borghaei H, et al: Carboplatin and pemetrexed with or without 
pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of 
the open-label KEYNOTE-021 study. The Lancet Oncology 17:1497-1508, 2016 
20. 
de Biasi A, Villena-Vargas J, Adusumilli PSJCCR: Cisplatin-Induced 
Immunomodulation: A Review of Preclinical and Clinical Evidence.clincanres. 1298.2014, 2014 

Page 43 of 43 
CONFIDENTIAL 
Version 9 dated 7/17/20 
 
21. 
Duffy A, Greten TJAoo: Immunological off-target effects of standard treatments in 
gastrointestinal cancers. 25:24-32, 2013 
22. 
Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus 
cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England 
journal of medicine 349:859-66, 2003 
23. 
Zargar H, Shah JB, van Rhijn BW, et al: Neoadjuvant dose dense MVAC versus 
gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. 
199:1452-1458, 2018 
24. 
Okabe K, Shindo T, Maehana T, et al: Neoadjuvant chemotherapy with gemcitabine and 
cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. 48:934-941, 2018 
25. 
Anari F, O’Neill J, Choi W, et al: Neoadjuvant Dose-dense Gemcitabine and Cisplatin in 
Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology 1:54-60, 2018 
26. 
Peyton CC, Tang D, Reich RR, et al: Downstaging and Survival Outcomes Associated 
With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle- 
Invasive Bladder Cancer. 2018 
27. 
Paller CJ, Bradbury PA, Ivy SP, et al: Design of Phase I Combination Trials: 
Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering 
Committee. 20:4210-4217, 2014 
28. 
Haanen J, Carbonnel F, Robert C, et al: Management of toxicities from immunotherapy: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119-iv142, 
2017 
29. 
Brahmer JR, Lacchetti C, Schneider BJ, et al: Management of Immune-Related Adverse 
Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical 
Oncology Clinical Practice Guideline. 36:1714-1768, 2018 
 
30. R Core Team (2013). R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.